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Abstract
The primary goal of this research is to determine the strategic system integration opportunities
for a segmented healthcare system with cost minimization and efficacy maximization objectives.
This research is inspired in part by the Defense Logistics Agency, which is trying to assess the
impact of integrating treatment selection processes across service clinicians. Specifically,
physician bias, patient volumes, leveraging economies of scale or costing structures, and
complex treatment efficacy calculations are considered by mathematically modeling three forms
of integration.
Multiple objective optimization problems are used to define efficient frontiers based on cost and
treatment efficacy. A novel comparative analysis method is applied to measure improvements in
efficient frontiers and a customized genetic algorithm solution is applied for the more complex
treatment selection problem. Results indicate that more integrated treatment selection protocols
lead to decreases in cost alongside increases in efficacy. Complex healthcare systems or systems
with higher variability in performance factors are found to have the greatest opportunity for
performance improvement.
The three studies in this research apply systems engineering concepts to flexibly characterize and
parameterize systems; inform policy including characteristics of attractive treatments; and
capture system dynamics and insights. However, this research is not intended to dictate
treatments to health professionals; set policy or give practitioners optimal allocations; fully
capture all of the intricacies of the treatment design process; or constrain research processes
associated with treatment design.
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CHAPTER 1
Introduction
The United States has the highest per capita healthcare costs in the world, yet lags behind
many developed countries in terms of population health and other system quality measures. Pate
(2008) estimates that the healthcare industry spends up to 54 percent of cost in waste each year.
Within the next ten years, healthcare costs are expected to double to 4.5 trillion dollars,
approximately one-fifth of the country’s gross domestic product (Terry, 2010). This ratio
implies that the United States will spend over 2.5 trillion dollars per year in preventable costs or
system inefficiencies by the year 2020.
In recent years, a significant portion of domestic public policy has focused on healthcare.
Concentrated policy debate seeking to address this issue has been ongoing since the early 1990’s.
Elected officials and system administrators have focused on healthcare accessibility and funding,
with limited attempts toward optimizing cost reduction or healthcare quality. The most wellknown and significant legislation came with the 2010 passage of the Patient Protection and
Affordable Care Act. This act, like other policy efforts, seeks to encourage health system
integration to decrease costs and improve effectiveness. Implementation of policy-based
integration efforts is complicated by a variety of issues including patient privacy, technology,
and patient and physician choice.
Much of the integration effort to date is heavily influenced by the fields of public policy
and healthcare economics. Yet, much of the integration potential involves medical supply chain
and information technology integration. Consequently, this dissertation provides a quantitative
approach to influencing healthcare policy with emphasis on supply chain and information system
integration.
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1.1 Healthcare System Integration
Specifically, this research is motivated by the system segmentation challenges, and the
associated integration opportunities, faced by the U.S. Department of Defense (DoD) Defense
Logistics Agency (DLA). These challenges and opportunities are reflective of those within the
broader healthcare system.
1.1.1 Defense Logistics Agency integration trends. The DLA is the Medical Material
Executive agent for the DoD and is responsible for end-to-end DoD supply chain logistics.
Though separated from other categories of DLA-managed products, the healthcare mission is
consistent with the broader DLA mission of consolidating and optimizing supply chains across
the defense enterprise. This mission is expressed in its National Inventory Management Strategy
(NIMS) to integrate DLA and service (e.g. Army, Navy, or Air Force) inventories into a single
system to take advantage of asset pooling and other supply chain best practices.
To facilitate integration, the DLA utilizes an electronic information system for medical
purchases. The system is referred to as the Theater Enterprise Wide Logistics System (TEWLS).
Using DLA funds, military services purchase medical supplies via TEWLS. The system is
capable of managing supply catalogs, orders, and invoices, as well as, the financial accounting
required for procurement in the enterprise business system.
1.1.2 Defense Logistics Agency segmentation challenges. Despite the intent of the
NIMS and the function of the TEWLS, significant segmentation remains. Individual services are
responsible for determining treatment protocols and managing associated order payments. DLA
has determined that different treatment protocols are used across different services for the same
patient condition. Service process managers may use different carrier services for the same set
of supplies with similar destinations.
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When investigated, the DLA finds these non-standardized treatment protocols have no
underlying explicit rational. The creation and persistence of such protocols is driven by two
factors: disparate views of treatment efficacy and limited view by treatment designers (note:
treatment designer is synonymous with physician in this research) of cost / supply chain impact.
Additionally, the service medical organization is increasingly being divided into specialists with
a sub-discipline biased view of a patient. The physician treats the patient according to the
disease associated with the specialty.
This segmentation leads to increased uncertainty, increased costs, and, likely, decreased
treatment efficacy. The impact of integration is further undermined as users make use of legacy
manual operations instead of exploiting the automation of TEWLS.
1.1.3 US Healthcare System integration trends. Many of the integration trends and
segmentation challenges found in DLA are mirrored and magnified in the US system.
Independent hospitals have united into regional healthcare systems to take advantage of
economies of scale. Group purchasing organizations (GPOs) have been created to translate
volume discount purchases into lower costs.
As with the DLA, much of the integration potential for the US healthcare system is
related to information systems. During early years, healthcare systems deployed information
systems as basic data storage systems to maintain schedules, patient treatment records, and
financial information. As technologies and analytics have evolved, systems are able to leverage
healthcare data to inform patient treatments, optimize logistics, and provide better coordination
for patient care.
Studies suggest that the adoption of emerging technologies for healthcare supply chain
management can mitigate healthcare concerns with coordination and communication (Zhenga et
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al., 2006). Many healthcare systems have implemented enterprise planning systems intended to
facilitate cost reduction and improve work process to improve patient care. Going forward,
systems like the National Health Information Network (NHIN) are being developed to improve
the quality and efficiency of public hospitals through establishing a mechanism for nationwide
health information exchange.
1.1.4 US Healthcare System segmentation challenges. The same segmentation issues
exist within the US system as in the DLA. Cost and efficacy is heavily influenced by treatment
selection at the individual or regional healthcare system level. Physicians (as treatment
designers) are shielded from a clear understanding of cost structure. Physicians have few
mechanisms to facilitate a collaborative process which might yield a system’s views of efficacy
and enable opportunities for standardization. As with DLA, the impact of increased physician
specialization also is a major source of segmentation in the US system.
The impact of information system integration is still limited. For example, providers are
reluctant to utilize shared information systems such as NHIN at the risk of compromising patient
confidentially, competitive advantages, or exposing system failures.
Segmentation also exists among healthcare providers abroad. Blendon et al. (2003)
survey issues in healthcare across five countries and discover high levels of patient
dissatisfaction with medical errors, communication, and coordination. As many U.S. providers
have implemented coordinated healthcare delivery practices to mitigate Medicare expenditures,
Peikes (2009) concluded that viable coordination programs do not yield significant Medicare
savings or improvements in quality.
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1.2 Problem Statement
Based on the challenges listed above, three forms of segmentation may be identified: (1)
separation of the physician / treatment designer from a systemic view of efficacy, (2) separation
of the physician / treatment designer from an understanding of supply chain cost structure, and
(3) separation of a patient condition according to specialization. Information system integration
efforts might assist in overcoming issues associated with the segmentation. However, integration
can be expensive and complex. As a result, this dissertation seeks to solve the problem: how
might one model and analyze pre- and post-integration system performance in a manner that
enables understanding of key system dynamics and prioritization of effort?
1.3 Research Objective
The primary goal of this research is to determine the strategic opportunities of system
integration for a segmented healthcare system seeking to balance cost and efficacy. Specifically,
the research serves to achieve five objectives:
1. Characterize forms of segmentation and associated integration opportunities. Three
different forms of segmentation are defined and considered associated with physician/system
efficacy valuation, supply chain behavior, and specialized medicine (to include efficacy
structure).
2. Represent pre- and post-integration policies in general quantitative models facilitating
optimization solution. Mathematical models build upon the proven systems engineering
principle that supply chain costs are best influenced during the design stage. Treatment
protocol determination provides the analog with product design. The intent of these models
is not to solve for implementable treatment protocols, but to represent the function of rational
systems given the associated integration policy. Four such models are developed.
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3. Develop solution approaches which enable the discovery of characteristics of “good
solutions.” For the different models developed in objective two, solution methods are
created, ranging from enumerative to heuristic to meta-heuristic. The solution methods yield
further understanding between the relationships of “good solutions.”
4. Recognize situations which present key integration opportunities. Based on factors exposed
during the model formation, experiments are designed and conducted to demonstrate
situations where integration might provide the most value.
5. Suggest specific policy adjustments based on the research insights. Throughout the
research, inferences are made from experimental results to determine the managerial,
technical, and social implications of treatment designs.
The issue of treatment design to promote cost effectiveness is highly sensitive due to its
potentially critical impact on a quality of life. As a result, the limitations of this research are
explicitly stated. This research does not intend to do the following:
1. Dictate treatments to health professionals. The key relationship in healthcare is that between
the physician (or other healthcare professionals) and the patient. The physician should retain
the choice of treatment, not be replaced by some automated optimization approach.
2. Fully capture all the intricacies of the treatment design process. The models in this
dissertation depict general situations relative to cost/efficacy tradeoff and associated
dynamics. The models are not intended to capture all of the relevant information needed for
treatment design of a specific set of diagnoses.
3. Set policy or give optimal treatment allocations. Due, in part to items one and two above, the
models are never expected to be used to suggest a treatment for a specific set of patient types.
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4. Constrain research process associated with treatment design. Treatment design is an
expensive and sophisticated process including much investment in research and
development. The impact of these costs and associated strategic decisions are not the main
considerations in model development (though fixed costs are included).
1.4 Research Significance
This research is innovative in that it borrows from core concepts found in systems
engineering, specifically in product design to explore opportunities in medical treatment protocol
design. Similar to the objectives in product design, this research seeks to determine the policies
for treatment design that minimize costs while maximizing efficacy for patients. System
transparency, process standardization, and resource consolidation are shown to lead to efficiency.
The research proposes a novel systems engineering approach to considering system
integration opportunities. Quantitative models are built as generalized representations of preand post-integration systems and used to emulate rational system behavior. The models are
solved under a variety of situational factors to better understand the nature of the integration
opportunity.
For optimization modeling and simulation, modification to the traditional multi-objective
optimization problem (MOOP) are proposed. Extensions to multi-objective representation,
solution, and performance management are noted as progressively complex models are formed.
The models incorporate the idea that patients may seek care for multiple health problems through
varying physicians and that treatments can affect more than one diagnosis for a patient. The idea
the supply chain cost and treatment efficacies are nonlinear and vary by volume of system usage
makes the research model more robust.
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1.5 Dissertation Outline
The remainder of the dissertation is organized as follows. Chapter 2 includes a
description of the integration process, treatment selection concept, modeling, experimentation,
and analysis consistent across the three chapters that follow it.
In Chapters 3 through 5, each of three different forms of integration are considered.
Figure 1.1 illustrates these forms of integration along with the models and characteristics
associated with the system before or after integration. The figure also shows the associated
forms of segmentation. Although the integration is shown as progressive, the integration need
not occur in this same sequence.

Figure 1.1. Three forms of healthcare system integration.
Chapter 3 investigates limited information visibility or bias in physician efficacy
valuation influences system performance. A review of physician tendencies in assessing efficacy
and cost is provided. Supply chain cost impact is evaluated using efficient frontiers of total
treatment cost versus total treatment efficacy. Techniques to mitigate physician (or institutional)
bias are proposed along with strategies to make practitioners informed participants of medical
supply chain management.
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Chapter 4 investigates physician understanding of supply chain cost structure and its
impact in designing medical treatment protocols. An optimization model is used to help
determine treatment selection strategies change under varying costing structures.
Chapter 5 builds on the preceding chapters to examine whole patient consideration and
more detailed efficacy models might impact system cost effectiveness. A modified multiobjective optimization problem is modeled to recognize synergies in treatment efficacies and
patient populations to achieve economies of scale.
Chapter 6 concludes this dissertation with an overview of the research methodology and a
discussion of possible extensions of this research. This chapter provides a consensus of the
conclusions found in the three research studies. Key findings are highlighted and presented with
strategic implications.
Throughout the document, associated literature is reviewed and described as an integral
part of the text. This approach is taken due to the multi-disciplinary nature of the research.
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CHAPTER 2
Research Foundation and Method
This dissertation provides a study of the impact of three forms of healthcare system
integration that might positively influence healthcare system cost (with emphasis on supply
costs) and quality. The three forms are considered progressively and associated with three forms
of segmentation introduced in Chapter 1. For each form of integration, a consistent process is
undertaken to enable modeling and analysis of pre- and post-integration system performance in a
manner that enables understanding of key dynamics and prioritization of integration effort. The
process includes the following steps:
1. Review literature relevant to the identified form of segmentation to characterize its impact
and develop an associated integration concept.
2. Create generalized quantitative models which might be solved to mimic rational system
behavior for pre- and post-integration policies. Again, the intent of these models is not to
solve for implementable treatment protocols. Four such models are developed. The models
use treatment design as the decision variable with a multi-objective goal to minimize cost and
maximize efficacy.
3. For each model developed, a solution method(s) is created, ranging from enumerative to
heuristic to meta-heuristic. The solution methods yield further understanding between the
relationships of “good solutions.” As a result, solution methods are constructed to produce
“efficient frontiers.”
4. Based on the characterization in step one, key environmental factors are identified and an
associated experimental design constructed and executed.
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5. Experimental output is compared and analyzed in order to determine the characteristics of
high leverage integration opportunities.
6. Inferences are made from experimental results to determine the managerial, technical, and
social implications of treatment designs.
This process is generalizable for a number of policy areas where system integration might be
considered and forms a key part of the contribution of this research.
The three forms of integration are addressed in Chapters 3 through 5 respectively. The
remainder of this chapter provides an overview of the common foundation across all the research
organized according to the process above.
2.1 System Segmentation and Integration Opportunities
Each chapter begins with a review of literature relevant to identified form of
segmentation. This review is used to characterize segmentation impact and develop an
associated integration concept.
2.1.1 Segmentation types. The three forms of segmentation were revealed in the case of
the Defense Logistics Agency and reflected in the US healthcare system as a whole. These
forms of segmentation are:
1. Those making treatment decisions are often separated from a system understanding of the
effectiveness of the treatment for the given patient condition. Treatment decisions may be
based on past experience often limited in frequency. Additionally, pharmaceutical
companies spend significant marketing dollars to influence physician views and, more
recently, to influence patient views. Deviations in efficacy evaluation for an individual
physician (or healthcare system) from a comprehensive system view, is termed treatment
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bias. The existence of such bias, even when unintentional on the part of the physician, can
undermine system performance.
2. Those making treatment decisions are often separated from an understanding of supply chain
cost structure. Doctors are often unaware of the costs associated with the treatments they are
designing. Even when cost is a consideration, variable unit costs are considered. This view
might not lead to cost efficient solutions given common supply chain cost structures.
3. Patient treatment is separated according to physician specialization. This approach tends to
drive a reactive approach to healthcare. It leads to different treatment designs being
administered to the same patient. Problems associated with this include limited proactive
actions, missed opportunities for treatment synergy, and potentially harmful side effects from
treatment mixing. Resolving this form of segmentation uses a novel form of efficacy
representation with enables consideration of the sensitive subject of healthcare rationing.
These forms of segmentation are described in more detail in Chapters 3 through 5.
2.1.2 Integration opportunities. For each case of segmentation, the mechanism
suggested to facilitate integration is information systems. For a number of years, healthcare
information systems have been used to automate business processes and in clinical applications
such as diagnoses, therapy, and surgery (Kulkarni, 2006; Mantas, 1992; Sneider, 1987). More
recently, healthcare reforms and alliances are prompting greater focus on integrating and
coordination throughout healthcare delivery systems worldwide (Kodner and Spreeuwenberg,
2002). Regulations such as HIPAA and requirements for cost reductions and quality
improvement are prompting greater use of shared information systems (Fadlalla &
Wickramasinghe, 2004).
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Despite the availability of healthcare information systems, enterprise integration has
always been problematic and slow in healthcare organizations (Khoumbati et al., 2006). Over
time, the implementation of healthcare information systems has become more complex due to
concerns for quality and integrity; the growth and evolution of the clinical services; hardwired
legacy systems; and the competitive nature of the healthcare industry (Berger & Ciotti, 1993;
Mandke, Bariff, & Nayar, 2002; Teisberg & Harvard Business Review, 1994). Adding to these
concerns, clinician awareness and acceptance is often regarded as a leading barrier to successful
adoption of healthcare innovations (Omachonu and Einspruch, 2010; Birken et al., 2012; and
Holden and Karsh, 2010). These difficulties provide the justification for this research, which
serves to identify integration opportunities with good value.
2.2 Policy Modeling
For this research, policies are modeled with treatment design as the decision variables
and dual objectives of cost minimization and efficacy (measure of healthcare system quality)
maximization. The model constraints are created to mimic rational behavior under the associated
policy.
Four policy models are needed to provide pre- and post-integration models for each of the
three integration forms. Policies in the system increase in terms of complication and integration
as one moves from the top to the bottom of Figure 2.1. Also note that the policy models are
titled according to the state of the segmentation factors related to efficacy, supply chain cost, and
patient view.
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Figure 2.1. Policy models developed in the research.
2.2.1 Treatment selection. Many cost efforts in healthcare attempt to reduce costs for an
already established mix of supply. This research builds on the system engineering concept that
the key opportunity for impact on supply chains is at the product design stage. The analogous
decision in the healthcare realm is the selection of treatment protocol by the physician or
healthcare provider. The term “treatment designer” is used for this role in the research.
Specifically, most healthcare expenditures in the U.S. are based on physician or
healthcare system decisions. Therefore, it is important to consider clinician perspectives when
examining treatment selection strategies. Studies suggest that many “decisions regarding
medical tests and treatments are influenced by factors other than the expected benefit to the
patient, including the doctor's demographic characteristics and concerns about cost and income”
(Bovier et al., 2005). Fortunately, recent studies are proving that healthcare integration systems
have significant, positive impacts on prescribing behaviors (Fortuna et al., 2009).
Note that a treatment protocol may consist of a single medicine or a combination of
medicine. Additionally, a treatment protocol might consist of a mix of proactive and reactive
treatment or a decision to “do nothing”. This generalization of treatment protocol provides much
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flexibility and enables more focus on the policy aspect of this research (rather than on solving
specific treatment design problems).
2.2.1.1 Patient condition / disease. The selection of treatment protocol is made in
response to the condition of the healthcare client – the “patient.” In the systems engineering
analogy, design decisions are made in an effort to provide good value in meeting customer
needs. Similarly, in healthcare, treatment designs should be made in a manner to address health
concerns, proactively and reactively, in a cost efficient manner.
The view of the patient in light of specialization influences the understanding of the
condition. For instance, a healthcare provider with an emphasis on reactive care might see the
patient as a specific disease or illness. This “disease” view is consistent with the majority of
current practice and is taken in Chapters 3 and 4. Chapter 5 addresses systems that enable
“whole patient” views.
2.2.1.2 Assignment problem. Establishing the connection between a patient type or
disease and a treatment protocol is a form of the classic assignment problem. For this situation,
operations researchers often make use of assignment models to determine the most appropriate
allocation of resources (Winston & Goldberg, 2004). A brief review of assignment problem
approaches follows.
The goal of any assignment problem is to determine the best solution for assigning some
set of items to another set of items. There are several different techniques or assignment
problem formulations designed to reach this goal according to vary system constraints. The
main difference between assignment problems is the use of cost / distance matrices for sites,
resources allocated to those sites, and the criteria or restrictions given in addition to the
requirements of the basic assignment problem (Levin, 2004). Figure 2.2 exhibits this taxonomy.
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Multicriteria Generalized
Assignment Problem
Multicriteria Quadratic
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Distance matrix
for positions

Multicriteria Generalized
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Figure 2.2. Evolution of the basic assignment problem adapted from Levin (2004).
Assignment problem differences can be denoted by the terms quadratic, generalized, and
multi-criteria. Any quadratic assignment problem is given added dimensionality to account for
the value of distances between sites that will be important in allocating assignments. When
resources are to be constrained to different positions, the problem becomes generalized to
account for the requirements of subsystems. As additional system constraints are added, the
problem is considered to have multi-criteria.
There are many specific assignment problems that fit within the categories outlined in
Figure 2.2. The following sections of this chapter discuss the formulation and implications of
four common assignment problems and describe how they may be used to allocate resources.
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Specifically, the properties of the mapping problem, general assignment problem, quadratic
assignment problem, and weapon-target assignment problem are explained.
2.2.1.2.1 Matching problem. The matching problem is fundamental in graph theory as it
seeks to find the optimal pairwise relationships for a set (Goemans, 2009). The focus of this
section is the minimum weight perfect matching problem for a bipartite graph. Consider the
graph shown in Figure 2.3. The set of elements in the graph are partitioned into two parts, thus
the name bipartite graph.
The goal of this type of matching problem is to find the minimal number of connections
called “edges” between the partitioned sets such that the total cost of said connections is
minimal. Additionally, the problem is said to be a perfect matching problem if none of the nodes
remain exposed, that is, there exist a connection across the partition for each node. A perfect
matching problem for a bipartite graph is also referred to as an assignment problem.

Matched Node
Exposed Node
Optimal Connection
Feasible Connection
Partition

Figure 2.3. Illustration of bipartite graph matching problem.
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2.2.1.2.2 General assignment problem. Assignment models have been used commonly in
healthcare for scheduling staff members (Day, 1985; Ozkarahan, 1991). These models have
been used to find solutions for more efficient treatment processes as well (Wang-Rodriguez,
Mannino, Liu, & Lane, 1996). On a larger scale, scientists have long argued that the use of
assignment models can be instrumental in quantifying performance and provide an effective tool
for selecting operational priorities, or strategic planning (Hannan, O'Donnell, & Freedland, 1981;
Lusk, 1979).
Consider a system in which a finite set of resources may be used to complete a number of
tasks. Some cost is incurred whenever a resource is assigned to a task. All tasks must but
completed and each task is assigned exclusively to one resource. For this scenario, the general
assignment problem may be used to determine the impact of various assignment strategies or the
structure of the most optimal resource assignment strategy (Eiselt & Sandblom, 2000).
First, let the decision to assign resource i to task j be represented by xij. Decision variable
xij will equal one if resource i is assigned to task j and zero otherwise. Second, assume that a
cost cij will be incurred if resource i is assigned to task j. Then, the nonlinear integer
programming model to solve the general assignment problem is formulated as follows:

min i  j cij xij

x

s.t.

i

x

ij

1  j

(2.1)
(2.2)

1  i

(2.3)

xij  0 or 1  i and j

(2.4)

i

ij

The objective function for this model ensures that the lowest cost strategy is chosen for
assignments. Equation 2.2 ensures that each task is assigned exactly once. Equation 2.3 ensures
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that each resource is assigned to complete exactly one task. Equation 2.4 is a binary constraint
for the decision variable.
Goemans (2009) provides insight on the characteristics of the general assignment
problem. If the integrality constraints of the general assignment problem are relaxed the problem
takes on an infinite number of fractional solutions. With the relaxation, the problem linear
program is polynomially solvable. However, with integrality constraints the problem becomes
nonlinear and more constrained than the linear program. Integrality constraints imply that the
minimizing solution for the integer program no less than the minimizing solution for the linear
program.
Of all assignment problems discussed in this chapter, the model for general assignment
problem is the most common as it may be adapted and applied for many scenarios. In healthcare
decision making, this model may be used to determine which tools to use during surgery, how to
assign patients to rooms, or the best treatment to prescribe for specified diagnoses. The latter
will be explored in following sections.
Unfortunately, most assignment problems are not a simple as assigning one resource to
one task for one cost. There are instances in which resources or tasks may require sequencing as
seen in an assembly line. Resource may be incapable of completing certain tasks as is seen in a
system with novice workers. It may also be the case that the cost of assigning a task is not
constant; it may be a function of time, quality, or depend or other assignments. Whatever the
case may be, the general assignment problem is commonly referenced due to its adaptability. A
few adaptations of the assignment model follow.
2.2.1.2.3 Quadratic assignment problem. The quadratic assignment problem has been
adapted to solve problems in many fields and applications including scheduling and location
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problems (Carlson & Nemhauser, 1966; Geoffrion & Graves, 1976; Koopmans & Beckmann,
1957) as well as in healthcare engineering (Elshafei, 1977). Commander (2005) provides a
detailed survey of various applications of the quadratic assignment problem. Similar to the
general assignment problem, the quadratic assignment problem seeks to determine the most cost
efficient way to assign resources to complete tasks. The key difference between the quadratic
assignment problem and the general assignment problem is that its cost function is a second
degree polynomial or quadratic because resources are not assigned independently (Koopmans &
Beckmann, 1957).
The quadratic assignment problem assumes a distance associated with completing a task
in addition to a cost. For example, consider a group of resources k and group of tasks l.
Resource i belongs to group k and task j belongs to group l. The decision in the quadratic
assignment problem is xab; whether object a of group b be assigned to an object from another
group. This decision is based primarily on the cost cij of assigning resource i to task j and the
distance dkl between resource group k and task group l. The mathematical model for the 0-1
quadratic assignment problem as defined by Commander (2005) is as follows:

min i  j  k l cij dkl xik x jl
s.t.

x



j

i

ij

1  j

xij  1  i

xij  0 or 1  i and j

(2.5)
(2.6)
(2.7)
(2.8)

The objective function in the formulation shows that associated costs and distance values
are incurred only when xik is assigned to xjl. The objective function ensures that the low cost,
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short distance strategy is chosen for assignments. Additionally, for the 0-1 assignment problem,
there is a one-to-one relationship between tasks and resources secured by model constraints.
Sahni and Gonzalez (1976) proved that the quadratic assignment problem is NP-complete
and also proved that ε-approximate solution for the problem is also NP-complete, making the
quadratic assignment problem among the "hardest of the hard" of all combinatorial optimization
problems. These characteristics suggest that finding optimality in polynomial time is unlikely
(Finke, Burkard, & Rendl, 1987).
2.2.1.2.4 Weapon target assignment problem. The weapon target assignment problem is
named such for its use in warfare (Eckler & Burr, 1972). This problem is concerned with
assigning weapons to hit a set of targets so the expected survival value of a target, more
commonly that of an enemy, is minimized (Ahuja, Kumar, Jha, & Orlin, 2003).
In this problem, the decision variable xij is the number of weapon type i to engage with
target j. Assume there are Wi weapons of type i available. Let cj be the value of target j. Let pij
be the probability of target j surviving a hit from one of weapon type i. Then pij xij is the
probability of target j surviving. The nonlinear integer programming model to solve the general
assignment problem is formulated as follows:

min  j cij i pijij
x

s.t.



j

xij  Wi  i

xij  0 and integer  i and j

(2.9)
(2.10)
(2.11)

The objective function for this model also ensures that the lowest expected value of
survival is chosen for assignments. Equation 2.10 ensures that the assignment of weapons does
not exceed the number of weapons available. Equation 2.1 ensures that a positive, whole number
of weapons is assigned.
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The weapon-target assignment problem becomes complex due to the nature of
information required to develop the model and its implied dimensionality. Consider that there
are two categories of data for this problem: target data and weapon data. The target data must
provide accurate information about the worth, strength, and two dimensions (a third may be
added for altitude) of location of each target. Only the location information is truly capable of
being quantified. Secondly, weapon data must provide insight on the chances that weapons will
hit a target and the gain of each hit.
Beyond data definition, much of the complexity of the weapon target assignment problem
is due to the dimensionality of the problem. For example, let there be t targets of interest for a
scenario that allows the use of p weapon types with ni being the number of weapons of type i.
This problem would require 4t items of target data and t i ni  p items of weapon data. Totally,
t (i ni  4)  p items of data would be required to solve this problem.

Day (1985) confirms the complexity of data requirements in an example where 600
individual targets, ten weapon types and 100 weapons of each type, result in a required 602,410
items of data to account for in assigning values and for the 3000 choice variables. Additionally,
the model for the weapon target assignment problem is nonlinear, so the problem grows more
unsolvable as dimensions are expanded. Targeting specialists commonly subdivided a set of
enemy targets into complexes to circumvent the complexity of large scale target assignment
problems. Concepts from the weapon target model are used in this research.
2.2.2 Solution representation. Three notions have been commonly applied to drive
solution of multi-objective optimization problems: utility theory (Keeney and Raiffa, 1976.),
weighted sum method (Kim and de Weck, 2006), and Pareto or efficient frontier optimization.
Konak et al. (2006) justifies the use of efficient frontier optimization over other methods.
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Figueira et al. (2005) provides a detailed discussion on this topic. As this research serves to
inform policy and not suggest specific cost-efficacy solutions, the efficient frontier method is
used for all models. An overview of efficient frontiers is provided below.
The concept of the efficient frontier was developed by economists to help select the most
optimal investment portfolio, the most efficient being that with the highest expected return for a
level of risk (Markowitz, 1959). Since inception, efficient frontiers have been a tool for defining
operational efficiencies across industries. Hollingsworth (2003) provides a review of the wide
use of efficient frontiers in private and public healthcare systems, including the Defense and
Veterans’ Administration hospitals.
Figure 2.4 is an adaptation of an efficient frontier for a healthcare system that defines
operational efficiency as the highest expected value of efficacy for a given cost (Kerno, 2008).
The frontier is the upper bound of the region of feasible operational strategies. The set of all
points that compose this boundary is the efficient set. Any physician that operates according to
an efficient point is utilizing best practices. In this diagram, physicians “A” and “B” are noted as
utilizing best practices.
In the case of in individual physician decision, physician “C”, the investment for current
operations could be used for more effective processes as with physician “A” or the current level
of efficacy could be reached at a lower cost as with physician “B”. For this reason, physicians
operating outside of the efficient set, such as physician “C”, are termed inefficient. This
information can be aggregated to produce system efficient frontiers.
Using efficiency frontiers, healthcare decision makers can better evaluate the cost
structure required to meet a given level of efficacy. The efficiency frontier provides a range of
optimality. Compared to using frameworks that output a single optimal solution for operation,
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the efficiency frontier allows flexibility for decision makers to determine how to align
operational goals with practices (Marler and Arora, 2004). Additionally, the relationships
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2.3 Policy Model Solution
For each model developed, a solution method(s) is created. The solution methods are
used to produce efficient frontiers which yield further understanding between the relationships of
“good solutions.” A key assumption in the modeling and solution approaches is that the
allocation is static (one-time). Issues of treatment impact over time are not included. Given the
desired use of the model output, the value of including time is minimal relative to its cost.
2.3.1 Multi-objective solution. The generic form of the multi-objective optimization
problem (MOOP) is commonly stated as follows:
min  F1  x  , F2  x  ,

s.t. g j  x   0j  1, 2,

, Fk  x 

,m

T

(2.12)
(2.13)
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hi  x   0i

(2.14)

Equation 2.12 represents k objective functions, equation 2.13 represents m inequality constraints,
and equation 2.14 represents e equality constraints. The vector x is the set of decision or design
variables.
Use of the MOOP stems from concepts in economics and mathematics such as
equilibrium and game theories. Concepts have been adapted to solve various engineering design
problems (Jendo et al. 1985; Psarras et al. 1990; Tseng and Lu 1990). Stadler (1988) provides
an extensive historical account and tutorial for the application of these problems. For the
problems in this research, multi-objective optimization is applied to manage the minimization of
total costs and maximization of efficacies simultaneously.
2.3.2 Solution methods. A wide variety of techniques exist for producing solutions to
optimization / search problems. A partial taxonomy of such methods is shown in Figure 2.5.
These research seeks to develop a variety of such methods with the additional requirement of
creating an efficient frontier rather than a single solution. Three general solution methods are
used for one or more of the models.
1. Complete Enumeration. This approach identifies all different combinations of decision
variables. Once evaluated, the set of solutions is processed to produce an efficient
frontier. That frontier is the known optimal frontier for the model.
2. Heuristic Search. This approach uses problem specific information in an attempt to
improve and broaden the perceived efficient frontier. Heuristic search is the fastest of the
three solution methods.
3. Genetic Algorithm. Evolutionary algorithms are unique among the listed meta-heuristic
methods because they maintain a set of solutions. That set might be improved and
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broadened and then processed to produce an efficient solution. The evolutionary
algorithm provides a balance of solution search breadth and speed and handles the final
non-binary representation of decision variables.
Problem Solving Methods
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Figure 2.5. Problem solving methods.
However, due to its role of mimicking rational behavior under a given policy to find good
solutions, the exact efficient frontier is not critical.
2.4 Integration Assessment
During the initial analysis of the segmentation challenge and associated integration
opportunity, key environmental factors are identified. These factors form the basis for the
experimental design constructed and executed in order to compare policies. Factor definitions,
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levels, and variable generation processes are described in the chapters. Relevant factors
considered in the dissertation include:
1. Variance in perceived treatment efficacy among treatment designers
2. Variance in fixed costs between treatments
3. Variance in variable costs between treatments
4. Variance in disease/patient condition severity
5. Variance in patient volumes / proportions
6. Opportunity for decreasing unit costs / volume discounts
7. Treatment efficacy as a function of dosage
2.4.1 Problem generation. Each of these seven factors is listed in the following table
with the levels used in the design of experiments. The combination of factors and factor levels
varies across policies. At most, when all factor levels are studied, total of 26 × 4 = 256 blocks of
experiments are implemented. Each block of experiments consists of ten replications for all
studies. This implies are maximum of 2560 observations.
Table 2.1
All possible experimental problem factors and levels.
Factor
1
2
3
4
5
6
7

Factor Description
Variance in provider’s perceived efficacy
Variance in fixed cost
Variance in variable cost coefficient
Variance in disease severity
Variance in provider’s patient volumes
Degree of volume discounts
Degree of efficacy curvature

Factor Levels
1-High, 2-Low
1-High, 2-Low
1-High, 2-Low
1-High, 2-Low
1-High, 2-Low
1-Concave, 2-Linear
1-Concave, 2-Linear, 3-Convex, 4-Random

For each form of integration examined in this research, an observation consist of the
same set of generated values. These values are shared between the pre- and post- integration
models and aggregated according to model formulation criteria. The manner in which the values
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are shared, along with solution transformation (see section 2.5.1), ensures that solution
comparisons are fair.
The levels for factors 6 and 7 are set to determine the curvature of costs functions and
efficacy functions, respectively. It is assumed that costs may have a linear relationship with
volume or a non-linear such that unit costs decrease as demands increase. Two levels are
included for this factor in the design of experiments to study the impact of these two
relationships. It is also assumed that efficacy may have a linear or non-linear relationships with
treatment volumes. Three levels are included in the design of experiments to study the impact of
three relationships. The first relationship, factor level 1, assumes that efficacies initially have
rapid growth utilization increases and eventually, the growth diminishes until virtually no gains
are possible. The second relationship, factor level 2, assumes that the growth in efficacies is
constant for each added unit of utilization. The third relationship, factor level 3, assumes that
efficacies initially have slow growth utilization increases and eventually, the growth increases
rapidly until virtually no gains are possible.
2.4.2 Random variable generation. The variables for factors 1 through 5 must be
generated to fit within a given interval and maintain a given level of variance. A beta
distribution Beta(α, β) is used to generate these random variables because its parameters can
implicate the mean, variance, and skewness of random variables on intervals of finite length.
The beta distribution is a continuous probability distribution defined on interval [0, 1]. Its
parameters, α and β dictate the shape of the distribution. The probability distribution function of
the beta distribution for 0 ≤ x ≤ 1 and the parameters α and β is as follows:

f  x; ,   

1
 1
x 1 1  x 
B  ,  

(2.15)
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In equation 2.15, B is a normalization function to ensure that the total probability integrates to
unity. The mean µ(X) and variance σ2(X) of a beta distribution random variable X with
parameters α and β are explained algebraically in equations 2.16 and 2.17, respectively.

X  



(2.16)

 

 2(X ) 


        1

(2.17)
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Figure 2.6 also illustrates how variance increases as the parameters for the beta
distribution approach zero. This can be proved by taking the limit as α and β approach zero of
equation 2.17. In general, variance increases as α and β are closer in value and/or closer to zero.
An exceptional feature of the beta distribution is that α = β = 1. Therefore, if an experimental
design requires high variance between randomly generated variables, α = β = 1. If an
experimental design requires low variance between randomly generated variables, α = β = 6.
The latter structures a beta distribution that is closer to a normal distribution that is truncated to
fit within a finite interval whereas the normal distribution lies on an infinite interval and,
therefore, is not reasonable the variables used in this research.
When a high level of variance is required for a variable in an experiment, a beta
distribution of high variance is used to generate random numbers and an accept/reject algorithm
is used to ensure that a sample variance no less than the population variance. Likewise, when a
low level of variance is required for a variable in an experiment, a beta distribution of low
variance is used to generate random numbers and an accept/reject algorithm is used to ensure
that a sample variance is no higher than the population variance. For example, the following is
an example of an accept/reject algorithm to generate random number set R having high variance.
Step 1: Generate x1, x2, …, xn i.i.d. from Beta(1,1)
Step 2: Compute the variance of the generated x1, x2, …, xn as S2
Step 3: If S2 < σ2, return to step 1. Otherwise, R = x1, x2, …, xn.
Now that the mean, variance, and skewness of randomly generated variables of the
experiments have been explained, the method to ensure a given interval for a random variable is
provided. Given constants a and b, expected value E(X), and variance V(X), the random
variables are translated that fundamental properties are maintained as follows:
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E  aX  b  aE (X)  b

(2.17)

V  aX  b  a 2 V(X)

(2.18)

Recall the accept/reject algorithm and parameters for the beta distributions used in this
research. The values for α and β (i.e. α = β = 1 and α = β = 6) dictate that low variance
corresponds to Var(X) ≤ 0.0192 and high variance corresponds to Var(X) ≥ 0.0833. Consider a
simple example for generating fixed cost di on an interval of [0, 100]. Matlab is used to generate
instances of low variance and high variance of fixed cost between three treatments. The instance
of low variance in fixed cost between treatments results in di = 61.50, 48.79, and 53.42 which
has a variance of 41.38 ≤ 1002 × 0.0192. The instance of high variance in fixed cost between
treatment results in di = 78.31, 18.04, and 9.87 which has a variance of 1397.10 ≥ 1002× 0.0833.
2.5 Integration Analysis
Experimental output from the prior step is compared and analyzed in order to determine
the characteristics of high leverage integration opportunities. This comparison consists of three
steps: solution transformation, solution comparison, and analysis of results.
2.5.1 Solution transformation. First, the solutions generated by both policies may need
transformation to a form for consistent evaluation. Evaluation is based on the more realistic
assessment of cost and efficacy given the form of integration under consideration. Specific
transformation details are described in the relevant chapters. In general, the efficient solutions
for a pre-integration model are transformed so that they may be evaluated under the objective
functions of the post-integration model formulation. This implies that solutions from the preintegration model cannot dominate solutions of the post-integration model as the transformed
solutions must fit within the post-integration model’s feasible solution set. The transformation
allows for fair comparison of the pre- and post- integration policies.
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2.5.2 Solution comparison. Second, efficient frontiers for the same experiment
produced by the two policies are compared. These efficient frontier analyses are used to compare
the performance of the problems generated and help characterize some properties of optimal
treatment protocols. Three measures were used to assess the relative performance of the models:
average improvement in efficacy, average improvement in cost, and average error rate. The
average improvement in efficacy and average improvement in cost are based on the “area of
opportunity” between the frontier of the pre- and post-integration policies.
This study employs a novel efficient frontier comparison method. Prior to developing
this analysis method a few existing metrics are explored. Namely, the methods employed by
Veldhuizen (1999), Veldhuizen & Lamont (1998), Zitzler & Thiele (1999), Srinivas & Deb
(1994). These strategies are described in Table 2.1. For example, Veldhuizen (1999) defines
error rate as the percentage of solutions from the pre-integration policy that are not on (inferior
to) the post-integration policy. Whereas, Veldhuizen & Lamont (1998) defines the general
distance between two problems as the average Euclidean distance between the closest members
from the pre-integration policy and the post-integration policy.
Table 2.2
Classic comparative metrics for multi-objective optimization problems.
Reference

Metric

Description

Veldhuizen
(1999)

Error rate

Percentage of solutions from EFpre that are not
members of EFpost

Veldhuizen & Lamont
(1998)

General distance

Average Euclidean distance from EFpre to closest
members of EFpost

Zitzler & Thiele
(1999)

Space covered

Size of the global dominated set in objective
space

Srinivas & Deb
(1994)

Spread

Distribution of individuals in EFpre over the nondominated region.
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For some experiments in this research, the global efficient frontier EFpost is known
through enumeration approaches. The efficient frontier EFpre is compared against EFpost to test
the performance based on measures of error.

To improve on existing strategies, the comparison

used in this study allows for fair, scalable comparison under varying factors. The “area of
opportunity” is a practical measure used for error assessment. Figures 2.6 and 2.7 illustrate the
area for opportunity for efficacy and cost as A2x and A2y, respectively. These areas of
opportunity are calculated by integrating the difference between EFpost and EFpre for ranges
intersecting costs or efficacy. Once the area of opportunity is determined, the average percent
efficacy and cost improvement of transitioning from EFpre to EFpost is calculated as

A2 x A1 x100% and A2 y A1 y 100% , respectively. A high percent increase indicates poor
performance of the solutions for EFpre in comparison to the solutions for EFpost.

Efficacy

“Area of Opportunity”

EFpost
EFpre

Cost
Figure 2.7. Regions of integration to assess efficacy improvement given cost range.
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Efficacy

“Area of Opportunity”

EFpost
EFpre

Cost
Figure 2.8. Regions of integration to assess cost improvement given efficacy range.
In instances where the ranges of cost (or efficacy) for two compared models do not
intersect, the area of opportunity for efficacy (or cost) is classified as undefined. This provides
two additional metrics which can be reported.
1. Efficacy undefined. The entire pre-integration frontier lies to the right of the post-integration
frontier.
2. Cost undefined. The entire pre-integration frontier lies to the below of the post-integration
frontier.
Both improvement metrics are presented as percentage and are easily interpreted.
2.5.3 Analysis of results. The third step of solution analysis involved the comparison of
pre- and post-integration policies, both holistically and according to experimental factors. The
five metrics are reported for each dimension of comparison. Underlying reasons for the results
are listed and unexpected results explained.
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2.6 Integration Implications
Finally, any policy suggestions that result from the research study are given along with a
summative description of that integration analysis. Chapters 3 to 5 follow addressing efficacy
integration and visibility; supply chain cost structure; and whole patient integration respectively.
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CHAPTER 3
The Impact of Efficacy Visibility
This chapter addresses the strategic implications of providing a system view of treatment
efficacy in a healthcare system where minimized cost and maximized efficacy are desired. Two
quantitative policy models are created to imitate pre- and post- integration and compared using
an experimental design assessing the performance impact of provider perspective variance,
varying costs, and demand volumes. System efficacy visibility is shown to help mitigate cost
and improve efficacy. Recommendations are made to leverage provider expertise and integrate
systems for shared treatment decision making.
3.1 Segmentation Challenge and Integration Opportunity
3.1.1 Background. Treatment design might be generalized as providing a high efficacy
treatment at a low cost. The understanding of the designer of treatment efficacy and cost is
critical for healthcare quality and supply costs. The clarity of design might be negatively
influenced by lack of visibility in terms of efficacy and cost, as well as issues of medical liability
and associated cost apathy, limited designer experience, and pharmaceutical/medical industry
marketing. A summary of efficacy and cost visibility follows.
Deviations in efficacy evaluation for an individual physician (or healthcare system) from
a comprehensive system view, is termed treatment bias. The existence of such bias, even when
unintentional on the part of the physician, can undermine system performance. Clinician bias in
patient treatment has been studied for years; mostly to help interpret variance in patient
outcomes. There is minimal study regarding the impact of clinician bias on supply cost of large
scale healthcare systems. Isbister et al. (2007) recommend that more emphasis be placed on the
issues of clinicians and patients rather than the vendor side of healthcare supply chain
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management. Clinician bias might also be institutional in the form of high intra-organization
variance in treatment protocol.
The idea of cost awareness (or lack of) among clinicians was presented as early as 1993
by Blum and Miller. The Blum and Miller (1993) research concluded that a large majority of
observed physicians could not accurately estimate treatment costs. Several other studies
followed with similar results. In 2000, Ernst et al. reported that a majority of physicians tend to
underestimate the cost of expensive treatments and overestimate the cost of less expensive
treatments. Reichert, Simon, and Halm (2000) concluded that most physicians have inadequate
access to drug cost data but stated that cost was an important factor. McGuire et al. (2009)
argues that cost should be of equal, if not more important, consideration in cases where
treatments are cost prohibitive. So why aren’t treatment costs weighed more heavily in
physician decision making? It may be because cost information is not as readily available
during treatment decision processes (Walzak et al., 1994; Fortuna et al., 2008; and Tseng et al.,
2006). This is due in large part by procurement and charging policies.
In addition to provider awareness, patient cost awareness also plays a role in cost
containment for healthcare and supply chain management. Many patients are concerned about
the cost of healthcare but few are fully informed about the costs included in healthcare
expenditures. It is also noted that patients are not likely to voice their cost concerns with
providers while treatment decisions are being made. Providers and patients often have the desire
to discuss out-of-pocket costs but can be dissuaded by perceived time constraints or because they
believe clinicians cannot offer solutions to out-of-pocket cost (Bovier, 2005).
In addition to enabling patient-clinician discussions for cost, public awareness campaigns
may also aid in reducing treatment costs. Studies show that affective public education
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campaigns can decrease prescription cost by almost $3 billion per year (Donohue et al., 2008).
Unfortunately, effectively public education campaigns are rare.
Instead of relying on uninformed clinician and patient decisions, decision support
systems can be integrated to improve awareness, decrease costs, and improve the quality of care.
Simple methods can be used to improve cost awareness and containment in healthcare (Roth et
al., 2001). Providing cost “cheat sheets” can lead to better awareness and less expensive
treatment decisions. Korn, Reichert, Simon, and Halm (2003) illustrate that information
pamphlets and basic cost education interventions improve physician knowledge and willingness
to consider costs in prescribing. The British Columbia has enacted healthcare cost containment
policies implementing generic substitution and a reference drug program. Polinski et al. (2008)
survey B.C. providers to determine that a majority believes that these policies are economically
and clinically appropriate. However, the study infers the government legislation has more
impact on acceptance than standalone physician training programs and controversy will ensue.
Andersson et al. (2009) conduct an extensive study of Swedish physicians and witness stronger
adherence to prescribing indicators over three years when decentralized budgets are presented to
providers, with greater buy-in from clinics in the public sector and from younger, residencytrained physicians. Sweden has also established a medication guide book that has been widely
accepted by physicians to inform medical decision making (Axelsson, 2008).
More advanced and computerized decision support systems also have a positive effect on
prescribing behaviors. In a clinical trial, Fortuna et al. (2009) experience 88% of clinicians
endorsing a medication alert system with 70% reporting that the system does not interfere with
work flow across 14 provider sites.
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Based on results from literature, it can be concluded that cost education programs and
decision support systems allow physicians to make more economic treatment decisions.
Additionally, more consolidated or standardized processes for treatment formulary lead to lower
system costs. Although, previous researchers have concluded that clinician awareness of costs is
an important factor in patient treatments, they have not modeled or conducted detailed
quantitative analyses on the impact of awareness. Additionally, they have not considered
strategies for obtaining or maintaining efficient treatment policies based on the trade-off between
cost and efficacy as established in this research.
3.1.2 Characterization. This chapter focuses on the integration opportunity for efficacy
visibility for treatment designers. Quantitative measures for treatment efficacy are numerous. A
common example is the disability-adjusted life year (DALY). This research keeps the measure
general due to its policy emphasis.
3.1.2.1 Patient volumes and treatment efficacies. Given a set of treatment designers and
their associated perceived treatment efficacy, a system view of efficacy needs to be derived.
Large healthcare organizations, such as the Veterans Affairs Health Administration, implement
incentive policies that encourage patient treatment based on expertise. Providers with expertise
in managing a given diagnosis are given incentives for serving high volumes of patients with the
diagnosis. Providers that serve low volumes of patients for given diagnoses are encouraged to
refer patients to providers with greater expertise. It is assumed that such a system will
experience treatment efficacies that are mostly impacted by such experts. Thus, system efficacy
is computed so that treatment efficacies are based on an average of volume-weighted provider
efficacies.
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3.1.2.2 Patient treatment unit costs. Several studies have concluded that providers
generally lack awareness of treatment cost. This lack of knowledge is assumed to increase
healthcare costs and, in turn, decrease the overall quality of care. Three views considered to
incorporate cost are as follows:
1. Designer is cost indifferent, seeking just to maximize efficacy.
2. Designer is cost considerate, trying to choose lower cost options for high similar levels of
efficacy.
3. Designer is cost educated, with some understanding of product price and its associated
variable and fixed costs.
In this study, models assume the third view in the form of a unit treatment cost, independent of
treatment volumes, or other procurement factors. This is the most generous view for designers
and most conservative in terms of making conclusions. Details of cost structures are considered
in Chapter 3. Basic characteristics of treatment cost variance are assessed to aid solution
strategies for more complex costing structures in future research studies.
3.2 Policy Model Formulation
Two policy models are developed. The first models a pre-integration policy of treatment
design based on individual efficacy perceptions, unit cost consideration, and disease specific /
specialization (IUD model). The second models a post-integration policy of treatment design
based on system efficacy, unit cost consideration, and disease specific / specialization (SUD
model).
3.2.1 IUD model (pre-provider integration). For the IUD, treatment efficacy values
are decided on a more independent basis by individual providers as opposed to a system with
more shared decision making. Supply costs are considered per unit. As previously mentioned,
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the cost factor assumed in this problem does not consider leveraging economies of scale from
combined treatment selection volumes or discount cost. Entry costs are not legitimately
accounted for either. The patients in this problem are viewed according to the providers’
specialties or per diagnosis as opposed to a system with capability to view and treatment the
whole of a patient’s complications. The main goal of treatment selection decision makers at the
clinical theatre level is to find the optimal values of the decision variables xijk: the binary decision
of provider k to select treatment i for diagnosis j to maximize the total perceived value of
efficacy while minimizing total cost.
The efficacy coefficient for this problem is ẽijk, provider k’s perceived efficacy value of
treatment i when applied to diagnosis j. The cost factor for treatment i is ci, the perceived unit
cost which is the sum of fixed cost di and variable cost si.
The optimization problem of selecting the xijk decision variables are formally expressed in
the IUD model as follows:
max i  j eijk xijk

(3.1)

min i  j ci xijk

(3.2)

s.t. i xijk

 1  j and k

(3.3)

xijk  0 or 1  i, j, and k

(3.4)

Note that this model emphasizes the disease and designer independence of the decision-making
process. This approach has the physicians assign a single treatment to each diagnosis with
binary representation. Patient volume is not considered. Recall that a treatment might be a
combination of proactive and reactive or a “do nothing” option. Unit cost information is
considered visible by the designer (which is generous based on the research indicating much cost
indifference). An alternative model might be including some representation of cost utility and
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visibility. Including this would further promote the attractiveness of integration. A key modeling
desire was to have a simple model of the most segmented policy in order to accommodate the
increasing complexity of modeling the integration impact.
3.2.2 SUD model (post-provider integration). With a system view of efficacy (given a
system view of unit cost), then treatment decisions are made on a system level. The decision
variable xijk is replaced by xij, the binary decision of for the system to select treatment i for
diagnosis j. The efficacy coefficient for this problem is ẽij, the system assessment of efficacy for
treatment i when applied to diagnosis j. Note that this research estimates ẽij =
(∑k Vjk ẽ ij )⁄(∑k Vjk ) where Vjk is volume of patient with disease j treated by physician k.
Again, this estimate is conservative in terms of revealing the impact of integration. The
optimization problem of selecting the xij decision variables are formally expressed in
SUD model as follows:
max i  j eij xij

(3.6)

min i  j ci xij

(3.7)

s.t. i xij

(3.8)

1  j

xij  0 or 1  i and j

(3.9)

Note that this model emphasizes the disease independence of the decision-making
process. This approach has the system assign a single treatment to each diagnosis with binary
representation. Patient volume is not considered. Unit cost information is considered visible by
the designer (which is generous based on the research indicating much cost indifference).
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3.3 Policy Model Solution
For this research, problems are sized and generated to enable solution through
enumeration. This approach is taken so that the entire set of feasible solutions might be
compared to the efficient frontier as in Figure 3.1. In practice when seeking the efficient
frontier, treatments might be ordered by cost or by efficacy. Treatments which are cost-efficacy
dominated might be eliminated on a disease by disease basis. Only disease cost efficient
solutions need be considered when constructing the system efficient frontier.
1.25

Total Efficacy

1

0.75

0.5

0.25
-0.98

-0.93

-0.88

-0.83

-0.78

-Total Cost

Figure 3.1. Feasible solutions with highlighted efficient frontier.
3.4 Integration Assessment
In the event that your figure caption is longer than one line, be sure that the subsequent
line is flushed to the left margin. See figure 2 for visual confirmation.
3.4.1 Selected factors. Based on the characterization in Section 3.1, the following
factors are considered in developing a design of experiments.
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3.4.1.1 Patient volume factors. For each problem, the demand volume of patients with
disease j serviced by each provider k, Vlk, must be known. The variability in Vlk is one factor
considered in the model. High variability indicates presence of treatment design by both experts
and inexperienced providers. Low variability indicates that patient volumes are balanced across
designers.
3.4.1.2 Efficacy factors. The parameters used to evaluate efficacy values in this study
are eijk, and Vlk. The basis for evaluating total efficacy between problems is that the perceived
efficacy may differ between providers and true efficacy may be estimated based on provider
expertise. Values of efficacy are normalized to range from 0 to 1 with 0 being ineffective and 1
being completely effective. Given that provider k’s perceived efficacy of treatment i for
diagnosis j is eijk, the system calculated efficacy according to ẽij = (∑k Vjk ẽij )⁄(∑k Vjk ). The
variability in perceived efficacy is a factor in the design of experiments. High variability
indicates many different perceptions regarding treatment efficacy. Low variability indicates
some consensus in terms of efficacy.
3.4.1.3 Cost factors. The parameters used to generate cost values in this research are di
and ai. The parameters for fixed costs and variable cost coefficients are varied from 0 to 100 and
then added to form a unit cost. It is assumed that the variable cost of treatment i tends to be
directly related to the relative efficacy of treatment i. Understanding that not all variable cost are
correlated to treatment efficacies, a “noise” factor is added such that the variable cost of
treatment i is si = ai ( ∑j ẽij )/( ∑j ẽij ) ± σi . The cost of selecting treatment i is calculated as di + si.
Variability in fixed costs and variability in variable costs are factors in the design of experiments.
3.4.2 Design of experiments. The objective of the experimental design is to understand
the relationship between parameters (variance in provider’s patient volumes, variance in
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provider’s perceived efficacy, variance in fixed cost, and variance in variable cost coefficient) on
the performance of treatment selection protocols of the IUD in comparison to the SUD.
Parameters are set in a manner that allows for inferences to be made relative to a system
progressing through the four policies of treatment protocols selection.
3.4.2.1 Generation of problem instances. In this study, a problem with three treatments,
three providers, and three diagnoses is examined. These parameters are generated using custom
programs in Matlab 7.12.0 (R2011a). This section discusses the design of experiments for
comparing solutions of the two formulated models. First, the methods used to generate their
values for the design of experiments are provided.
3.4.2.2 Random value generation. The values for di, eijk, ai, and Vlk, are randomly
generated from beta distributions. The parameters are translated using fundamental properties of
expected value and variance so that the expected ranges and variances for problem parameters
are maintained. For parameters di, eijk, ai, and Vlk, low variance corresponds to Var(X) ≤ 0.0192
and high variance corresponds to Var(X) ≥ 0.0833. Accept and reject logic is used to ensure
that the desired level of variance is maintained in the generation of the four factors with different
levels of variance. The purpose of using the beta distribution is to ensure that values lie within a
desired range (avoiding the disadvantages of truncation), maintain the desired level of variance,
and may be skewed from the central value of parameter’s range (Fox, 1963).
The Matlab code for each of the random number generators is found in the APPENDIX.
The problem parameters varied as a part of this research are summarized in Table 3.1. Ten
replications are executed for each factor level combination in the design for a total of 160
observations.
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Table 3.1
Study 1 experimental problem factors and levels.
Factor
1
2
3
4

Factor Description
Variance in Perceived Efficacy between Providers
Variance in Patient Volumes between Providers
Variance in Fixed Costs between Treatments
Variance in Variable Costs between Treatments

Factor Levels
1-High, 2-Low
1-High, 2-Low
1-High, 2-Low
1-High, 2-Low

3.5 Integration Analysis
Based on the design of experiments, a total of 160 observations were used to assess
model performances. Enumeration was used to find optimal efficient frontiers. Efficient
solutions of the IUD and SUD models are evaluated using the system efficacy. Note that given
the model solutions, only the decision variables, unit cost, and system efficacy are used in this
evaluation. Patient volume, supply chain cost structure, and efficacy utility are not considered
(though these factors are considered in subsequent chapters).
3.5.1 IUD-SUD Comparison. Table 3.2 lists the performance results of the IUD relative
to the SUD by experimental factor. Note that in this study, there were no instances of undefined
solutions (either efficacy or cost). As expected, the SUD outperforms the IUD across all
performance measures. Also, the IUD tends to perform closer to the SUD when there is low
variance in problem factors. Overall, the average improvement in cost, improvement in efficacy,
and error rate are 10%, 5%, and 42%, respectively. The following sections provide details of
performance based on each experimental factor.
3.5.1.1 Provider variances. The average improvement in efficacy is a consistent 5% for
high and low levels of variance in perceived efficacy. It is expected that this result occurs as
variance in perceived efficacy between providers can be mitigated through system integration
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and share treatment protocol selections. However, the corresponding cost of solutions made
based on perceived efficacies results in decreased performance. This decreased performance is
amplified as the variance in perceived efficacy between providers is increased. According to the
average changes in cost and error rate, the IUD performs better when the variance in perceived
efficacy between providers is classified as low. The average change in cost is increased from 6%
to 12% and the average error rate is increased slightly from 41% to 43% as variance in this factor
is changed from low to high.
Table 3.2
Average improvement of the SUD relative to the IUD.
Factor Levels
Variance in Perceived Efficacy
between Providers
High
Low
Variance in Patient Volumes between
Providers
High
Low
Variance in Fixed Costs between
Treatments
High
Low
Variance in Variable Costs between
Treatments
High
Low

Improvement in
Cost

Improvement in
Efficacy

Average Error
Rate

12%
6%

5%
5%

43%
41%

11%
6%

6%
5%

42%
43%

11%
7%

8%
2%

51%
33%

9%
8%

6%
5%

42%
43%

3.5.1.2 Patient volumes. Patient volumes were also used in the formulation of total cost
and total efficacy values. Accordingly, this factor does show an impact on performance that is
similar to the trends in variance in perceive efficacy between providers. The average change in
cost is increased from 6% to 11% as variance in patient volumes between providers is increased.
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The average change in efficacy is relatively unchanged, increasing from 5% to 6%. The average
error rate is decreased slightly from 43% to 42% as the variance in this factor is changed from
high to low.
3.5.1.3 Fixed costs. All performance values are increased as the variance in fixed cost
between treatments is increased. The average change in cost is increased from 7% to 11%, the
average change in efficacy is increased from 2% to 8%, and the average error rate is increased
from 33% to 51% as variance in this factor is changed from low to high. Improvements due to
this factor provide the most support for providers to share treatment selection protocols. Over all
factor levels, the lowest improvement in efficacy (2%) occurs when the variance in fixed cost
between treatments is classified as low. Efficacy is not directly implied in the calculation of
fixed costs as in the case of variable cost (refer to cost factors). Fixed costs are random or
unbiased to treatment efficacies. Without making decisions for treatment selection in lieu of
fixed cost, performance in decreased.
3.5.1.4 Variable costs. Unlike fixed costs, variable costs are assumed to be related to
treatment efficacies in this research. Therefore, if the efficacy of a treatment increases, the
variable cost of the treatment is also expected to increase. The efficient frontiers for the IUD and
SUD will make proportionate shifts. Study results show relatively little change for all
performance measures as levels for variance in variable costs between treatments change. The
average improvement in cost changes from 8% to 9%, improvement in efficacy changes from
5% to 6%, and error rate changes from 43% to 42% as the variance in this factor is changed from
low to high.
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3.6 Integration Impact
3.6.1 Solution characterization. All solutions that satisfy the inequalities of the SUD
model are basic feasible solutions. These solutions can be elements of the efficient frontier or
inefficient solutions. Recall that the design of experiments employed three treatments and three
diagnosis. Therefore, 27 basic feasible solutions were generated for each of the 160 observations
of the SUD. This advantage was exploited to explore characteristics of basic feasible solutions
that are more difficult to observe in the following studies. The solution sets of models in the
following chapters will have more complex dimensions and contain non-integer elements
making these models exponentially more difficult to solve. Before developing the studies in
chapters 3 and 4, key characteristics were observed to provide insight for solution heuristics.
3.6.1.1 Frontier navigation. Given a solution on the efficient frontier, one need only
consider changes in the treatment mix that increase efficacy in moving toward a higher efficacy
solution (and vice versa for lowering cost). A heuristic that proved effective was a one treatment
swap. The treatment with the highest change in efficacy relative to change in cost is attractive
when a higher efficacy point on the frontier is desired. The treatment with the highest change in
cost relative to change in efficacy is attractive when a lower cost point on the frontier is desired.
When using such a one swap heuristic, one can check for any options where the incremental
impact in favorable in terms of efficacy and cost (in case the swap has taken the procedure away
from the efficient frontier).
3.6.1.2 Concave efficient frontier. Occasionally, two points on the efficient frontier
might be endpoints on a line segment that dominates another point on the efficient frontier. The
concave efficient frontier eliminates all such points. That line might represent a gradual shift
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between the solutions associated with the endpoints. That shift could lead to better performance
than with the dominated efficient frontier point. This concept is used in future chapters.
3.6.1.3 High efficacy/low cost regions. An interesting trend was noticed when adjusting
efficacy variances or cost variances. In particular, as the variances between treatment efficacies
increase, the frontier solutions within regions of high efficacy tend to remain as frontier solutions
in the high efficacy region as other parameters remain unchanged. As the variances between
treatment unit costs increase, the frontier solutions within regions of low cost tend to remain as
frontier solutions in the low cost region as other parameters remain unchanged.
Figure 3.2 illustrates the change in frontier solution locations as variances in treatment
cost and efficacy are increased. Frontier solutions in the high efficacy or low costs regions are
highlighted. In order for provider “C” to perform as well as provider “A” or “B”, provider “C”
must increase total efficacy without sacrificing cost or decrease total cost without sacrificing
efficacy. A similar concept was exhibited when exploring the basic feasible solutions of the
SUD. When moving from the more inefficient solutions toward solutions of the efficient
frontier, it is shown that there are as many as three paths to improve the performance inefficient
solution toward the efficient frontier:
1. Decrease costs at a faster rate than decreasing efficacies.
2. Increase efficacy while decreasing costs.
3. Increase costs and increase efficacy.
Referring to Figure 2.4, these types of transitions can lead to efficient solutions to the
right of provider “B”, efficient solutions between providers “A” and “B”, or efficient solutions to
the left of provider “A”. Thus heuristic solutions much focus on the breadth and quality of the
produced efficient frontier.
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Figure 3.2. High efficacy and low cost regions along the efficient frontier.
3.7 Chapter Summary
The study discussed in this chapter models and assesses provider integration for
healthcare supply chain management. The study examined considers the implications of
information visibility in informing treatment efficacy. A unique performance assessment
method is proposed so that system performance may be evaluated in a more practical manner.
Using this assessment method, it is determined that informing provider decisions in treatment
selection protocols has a positive impact on overall system cost and efficacy. Subsequent studies
will explore the intricacies of treatment interactions, patient severity levels, and complex
treatment costing structures. The observed system characteristics are further explored in
chapters 3 and 4 to develop solution techniques for more complex models.
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CHAPTER 4
The Impact of Supply Chain Visibility
The primary goal of this study is to determine the strategic implications of considering
supply chain cost structure in creating treatment designs. A full design of experiments is
conducted to determine the performance impact that order-volume discounts, provider variance,
varying costs, and demand volumes have on treatment selection protocols. A heuristic solution
technique is employed to help comprehend processes involved in efficient treatment protocol
selection. Recommendations are made to integrate treatment selection protocols, improve cost
awareness among providers, and leverage economies of scale through shared and standardized
procurement and allocation policies.
4.1 Segmentation Challenge and Integration Opportunity
A substantial benefit of new healthcare enterprise integration systems is that they may be
used to exploit and improve supply chain logistics. Best practices can be observed and used to
improve procurement policies. Here, the impact of treatment selection protocols in an
integrating healthcare supply chain is explored.
4.1.1 Background. To date, healthcare supply chain operations account for 30 to 40
percent of healthcare cost, second only to personnel costs ("The Integration of Innovation and
Clinical Need: ROI - the Mercy Supply Chain Story," 2002). Gupta and Orbe (2009) discuss a
report from Arizona State University, labeling United States healthcare inefficient and expensive
as providers spend 31 to 67 percent of operating budgets on supply chain processes. Since costs
are assumed by patients, physicians are less concerned with cost and equity when prescribing
treatment designs. Most hospitals allocate patients’ fees according to charges made in
perioperative services (i.e. the period around patient operations), pharmaceuticals, and materials.
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Likewise, their view of supplies is distributed into these three categories of patient fees.
However, in a more transparent supply chain, hospitals have more access to the details in supply
costs and are better able to pinpoint and mitigate costs attributed from 3PL, wholesalers, and
consignment (Darling & Wise, 2010). Costs from shrinkage and stock-outs are also better
understood and easy to avoid.
A few researchers have investigated the impact of consolidating and standardizing
treatment selection decisions of clinicians in relation to supply chain management. Kelle et al.
(2012) address the conflict of formulary or product variety (preferred by physicians) and
economies of scale (preferred by pharmacy directors) for a local hospital. Pre-intervention, the
hospital employed an inventory ordering policy, which resulted in high frequency of shortages
and emergency refills based on user “experience” instead of statistical predictive modeling
solutions. The hospital transitioned to using drug depots that automate orders based on a (s, S)
policy. Mathematical models were used to determined that the hospital’s previous inventory
policies were suboptimal, increased formulary, resulted in increased refills, and, thus, higher
order costs and labor requirements.
4.1.2 Characterization. The model in this chapter assumes that treatment efficacies
have been defined at a system level based on disease. The volumes of patients with each type of
diagnosis are known. This level of characterization is consistent with Chapter 3.
The key difference in this chapter is that supply chain costs are known at the structural
level. For the purpose of the research, this is characterized by three measures.
Supply chain fixed cost (entry cost) is the cost associated with operating the supply chain
independent of the volume required. If the treatment volume is zero, then there is $0 fixed cost.
Supply chain variable cost is some measure of the rise in cost as a function of the rise in
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treatment volume. Cost/volume shape indicates the change in supply chain variable cost as a
function of treatment volume. A linear shape means that variable cost is volume indifferent.
More common shapes are sublinear based on economies of scale and volume discounts. In the
IUD and SUD models from Chapter 3, fixed costs as defined here was $0, variable costs were
based on unit costs, and the associated shape was linear.
A graph showing a supply chain with fixed costs and a sublinear shape is shown in Figure
4.1. Note that for a given increase in volume, the associated cost is much higher when the
treatment volumes are lower. The assumptions for how each of these known parameters is
manipulated to formulate models are provided in the following section.
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Figure 4.1. Supply chain cost structure.
4.2 Policy Model Formulation
Two policy models are considered. The first models a pre-integration policy of treatment
design based on system efficacy perceptions, unit cost consideration, and disease specific /
specialization (SUD model from Chapter 3). The second models a post-integration policy of
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treatment design based on system efficacy, system cost consideration, and disease specific /
specialization (SSD model).
4.2.1 SUD model (pre-cost integration). With a system view of treatment efficacy
values, the goal of treatment selection decision makers at the system level is to find the optimal
values of the decision variables xij:, the binary decision for all providers in the system to select
treatment i for diagnosis j to maximize the total system efficacy while minimizing total cost.
The MOOP model can be modified and simplified into the following form. Maximize the
system’s total (or volume-weighted) efficacy value and minimize the total cost, subject to
equality constraints to imply that:


One treatment must be selected for each diagnosis.



Treatment selection decisions are binary.
The optimization problem of selecting the xij decision variables are formally expressed in

the same SUD model from Chapter 3 as follows:
max i  j eij xij

(4.1)

min i  j ci xij

(4.2)

s.t. i xij

(4.3)

1  j

xij  0 or 1  i and j

(4.4)

Note that this model emphasizes the disease independence of the decision-making process.
Patient volume is not considered. Unit cost information is considered visible by the designer
(which is generous based on the research indicating much cost indifference).
4.2.2 SSD model (post-cost integration). The decision variables for this model assume
the same form as in the SUD. However, the values of this vector are assessed with a different
cost structure. In this model, the cost constants for treatment i are variable cost coefficient si,
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entry cost coefficient di, the degree of volume order discounts ui where 0 < ui < 1, and the
volume of demand for diagnosis j Vj. These factors are used to drive the assessment of cost
u

associated with treatment i in the SSD as ci = di yi +si ( ∑j Vj xij ) i where xij is defined as with the
SUD model and yi is a binary variable set to 0 if no treatment i is used and 1 otherwise.
However, in the SUD, ci = di +si as explained in Chapter 3.
The SSD model can be modified into the following form. Maximize the system’s total
efficacy value and minimize the total entry cost plus variable volume-based cost of treatments,
subject to the each of the following constraints:


One treatment must be selected for each diagnosis.



A one-time entry cost is incurred when at least one unit of a treatment is supplied.



Treatment selection decisions are binary.
The optimization problem of selecting the xij decision variables for this problem is

formally expressed in the SSD model as follows:
max i  j eij xij
min  i  di yi  si


s.t. i xij



(4.5)

 V x 

ui

j

j

ij

(4.6)




(4.7)

1  j

xij  Myi  0  i

(4.8)

xij  0 or 1  i and j

(4.9)

j

yi  0 or 1  i

(4.10)

Equation 4.8 is used to set the value of yi to drive the inclusion of entry costs in the total cost
computation. In this equation, yi is one if any xij is one for any j and zero otherwise. This
formulation requires the M must be as large as any reasonable value for ∑j xij ∀ i.
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4.3 Policy Model Solution
For this research, problems are sized and generated to enable solution through
enumeration. This approach is taken so that the entire set of feasible solutions might be
compared to the efficient frontier. However, for larger more complex problems, the non-linear
objective function and fixed cost inclusion complicated traditional optimization methods. A
heuristic solution technique is proposed to estimate the frontier of efficient treatment protocols.
4.3.1 Heuristic solution. The heuristic is established in the section based on the
following:


Adjacent points on the efficient frontier tend to have similar solutions.



Entry costs have a higher impact on unit cost when treatment volumes are low.



Transitions between efficient points tend to avoid incurring entry costs.



As costs increase, the increase in efficacy tends to diminish creating points that appear to be
on a concave front.
For this heuristic, the fixed cost di, the standard value of efficacy eij, the discount cost

coefficient si, the degree of the volume discount ui, and the demand population Vj must be
known. A current operational strategy or feasible solution xij must be established such that
exactly one treatment is selected for each diagnosis. Considering that few decision swaps tend to
occur between adjacent efficient solutions, the heuristic estimates the change in total efficacy and
total cost incurred from swapping one treatment at a time.
4.3.1.1 Efficacy and cost tradeoff estimation. A strategy to estimate alternative
treatment costs and efficacies is proposed from observing that very few decision swaps occur
between efficient solutions and that entry costs have a higher impact on unit cost when treatment
volumes are low. For this strategy, it is assumed that swaps are evaluated one at a time. When
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considering alternative treatment decisions in this problem, it is relatively easy to capture the
change is efficacy. The change in efficacy E is the difference in the dot product of efficacy
and the new decision and the dot product of efficacy and the initial decision. The nonlinear
relationship between costs and treatment volumes makes the treatment selection problem more
complex than if there were a linear relationship between costs and treatment volumes.
A rapid estimate for the increase in cost due to one treatment swap is proposed. Consider
that a swap is made in an initial solution xo resulting in solution xf. The initial volume of a
treatment Vo, becomes Vf after the swap. Decision makers may decide to consider the average
unit cost for treatment to evaluate the change in cost. In this problem, the average unit cost for a
treatment with volume v is as follows:
u

 d  sv , v  0
AC (v)   v

otherwise
0,

(4.11)

The cost AC incorporates the fixed cost of d, variable cost s, and some degree of
curvature u which implies a nonlinear relationship between cost and volume when u ≠ 1.
Decision makers may decide to consider the instantaneous change in cost for treatment i to
evaluate the change in cost. In this problem, the instantaneous change in cost is the derivate of
the cost function with respect to u at a given volume v or




SC (v)  usv
0,

u 1

, v0
otherwise

(4.12)

The iterative solution technique for this research considers a weighted combination of the
values AC and SC. When there is a small change in treatment volumes, AC is given more weight
so that fixed costs will have a greater impact of total cost. When there is a large change in
treatment volumes, SC is given more weight because the impact of fixed costs begins to
diminish. The weighted estimate for the change in cost is evaluated as ∆𝐶 = 𝛼𝐴𝐶 + (1 − 𝛼)𝑆𝐶
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where
V f  Vo
, Vo  V f

 Vf
 
V Vf
 o
, V f  Vo

 Vo

(4.13)

Figure 4.2 illustrates the relationships between AC and SC along a cost curve where Vo <
Vf and when Vf > Vo. Notice from this figure that the average unit cost for a treatment AC is
always based on the initial volume of a treatment. This reflects the idea that decision makers use
the baseline average to predict opportunity cost.
Vf < Vo

cost

cost

Vo < Vf

SC

SC

AC
AC
Vo

Vf

treatment
volume

Vf

Vo

treatment
volume

Figure 4.2. AC and SC evaluation based on shifts in treatment volumes.
The instantaneous change in cost SC is always based on the large treatment volume. This
reflects the idea that decision makers are most interested in the rise or fall in cost based on the
highest volume of use. At this volume, the incremental cost per unit is relatively low. This
strategy to estimate alternative treatment costs is used in the heuristic proposed in the following
section.
4.3.1.2 Locating improved solutions. After estimating for alternative treatment costs and
efficacies have been determined, it is possible to evaluate which alternative improves upon
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current operations. The observations discussed in Chapter 3 help to determine these alternatives.
Specifically, if it is possible to improve upon the current operations, it is done by in one of three
ways: (1) finding a solution with lower cost and lower efficacy that has equal or higher efficacy
per cost, (2) finding a solution with lower cost and higher efficacy that has equal or higher
efficacy per cost, or (3) finding a solution with higher cost and higher efficacy that has equal or
higher efficacy per cost. Based on these three criteria, a search routine is proposed to find
improve frontier points within three regions. The relationship between an efficient frontier, these

efficacy

regions and a feasible solution is exhibited in Figure 4.3.

Region 3
Region 2

Region 1

Po
cost

Figure 4.3. Regions of improvement for candidate swap decisions.
In Region 1, a swap will have a lower cost and lower efficacy than the current solution
values, Po. The swap in this region will result in the lowest possible change in efficacy per
change in cost. In Region 2, a swap will have a lower or equal cost and an efficacy greater than
or equal to the current solution values, Po. The swap in this region will be furthest away from
the current decision. In Region 3, a swap will have a higher cost and a higher efficacy. The
swap will have the highest possible change in efficacy per change in cost. Any solution that
results in a higher cost for a lower efficacy is less efficient than current solution values, Po, and,
therefore, is not considered as a candidate for swapping.
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Based on the searches for swaps in each of these regions, as many as three new solutions
can replace the current operational solution. Searches for improvements beyond found solutions
may continue until consecutive searches are equal or close enough or the allotted number of
iterations for a search is reached. The following heuristic algorithm details this search process
for efficient treatment protocols.
4.3.1.3 Heuristic process. Based on the solution characteristics of the SSD, a six step
heuristic is used to provide a close estimate for the efficient frontier. The six steps are as
follows:
1. Problem initiation. It is assumed the current feasible solution for operations or that a feasible
solution of interest is known. The problem is initiated with this solution being a candidate
member of the solution set and its objective function values being candidates for the efficient
frontier.
2. Decision swap. One swap is made for an element of the solution set. The resulting solution
is considered a candidate for the efficient solution set and must be compared to alternative
solutions prior to being declared efficient.
3. Swap comparison. The proposed technique for estimating an alternative treatment cost and
efficacy are used to determine possible improvements from a swap. The estimated changes
in cost and efficacy are vetted for improvement upon solutions present in Region 1, 2, or 3 of
the basic feasible region.
4. Solution and efficient frontier update. When candidates for efficiency are found to improve
upon a compared solution, the compared solution is replaced the by the candidate solutions.
The corresponding objective function values of the compared solutions are replaced as well.
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Up to three candidate solutions may be selected to replace the compared solution based in
searches in Regions 1, 2, and 3.
5. Efficient frontier concavity check. As a solution set is developed, it is important to ensure
that the efficient frontier set maintains concavity. This check is done periodically, in
declared intervals, during the heuristic search. Points that violate the requirement for
concavity are removed along with the corresponding solutions.
6. Stopping criteria evaluation. The heuristic may be stopped based on at least one of two
criterions: The distance between the efficient frontiers of consecutive searches is less than a
desired epsilon or the maximum number of iterations is reached. If these criterions are not
violated, the search for the efficient frontier continues.
A figure depicting the algorithm in detail is shown in Figure 4.4.
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Figure 4.4. SSD heuristic procedure.
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N
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4.4 Integration Assessment
4.4.1 Selected factors. Based on the characterization in Section 4.1, the following factors
are considered in developing a design of experiments.
4.4.1.1 Patient volume factors. For each problem, the demand volume of patients with
disease j serviced by each provider k, Vlk, must be known. The variability in Vlk is one factor
considered in the model. High variability indicates presence of treatment design by both experts
and inexperienced providers. Low variability indicates that patient volumes are balanced across
designers.
4.4.1.2 Efficacy factors. The parameters used to evaluate efficacy values in this study
are eijk, and Vlk. The basis for evaluating total efficacy between problems is that the perceived
efficacy may differ between providers and true efficacy may be estimated based on provider
expertise. Values of efficacy are normalized to range from 0 to 1 with 0 being ineffective and 1
being completely effective. Given that provider k’s perceived efficacy of treatment i for
diagnosis j is eijk, the system calculated efficacy according to ẽij = (∑k Vjk ẽij )⁄(∑k Vjk ). The
variability in perceived efficacy is a factor in the design of experiments. High variability
indicates many different perceptions regarding treatment efficacy. Low variability indicates
some consensus in terms of efficacy.
4.4.1.3 Cost factors. The parameters used to generate cost values in this research are di
and ai. The parameters for fixed costs and variable cost coefficients are varied from 0 to 100 and
then added to form a unit cost. It is assumed that the variable cost of treatment i tends to be
directly related to the relative efficacy of treatment i. Understanding that not all variable cost are
correlated to treatment efficacies, a “noise” factor is added such that the variable cost of
treatment i is si = ai ( ∑j ẽij )/( ∑j ẽij ) ± σi . The cost of selecting treatment i is calculated as
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. Variability in fixed costs and variability in variable costs are factors in the

design of experiments.
4.4.2 Design of experiments. The objective of the experimental design is to understand
the relationship between parameters (variance in provider’s patient volumes, variance in
provider’s perceived efficacy, variance in entry cost, variance in variable cost, and different
shapes) on the performance of treatment selection protocols of the SUD in comparison to the
SSD. Parameters are set in a manner that allows for inferences to be made relative to a system
progressing through the four policies of treatment protocols selection.
4.4.2.1 Generation of problem instances. In this study, a problem with three treatments,
three providers, and three diagnoses is examined. There are five parameters used to generate the
two problems in this research. The List of Symbols defines these parameters. These parameters
are generated using custom programs in Matlab 7.12.0 (R2011a). This section discusses the
design of experiments for comparing solutions of the two models. First, the methods used to
generate their values for the design of experiments are provided.
4.4.2.2 Random variable generation. The values for di, eijk, ai, and Vlk, are randomly
generated from beta distributions as described in Chapter 3. The Matlab code for each of the
random number generators is found in the APPENDIX. The problem parameters varied as a part
of this research are summarized in Table 4.1. Ten replications are executed for each factor level
combination in the design for a total of 320 observations.
Table 4.1
Study 2 experimental problem factors and levels.
Factor
1
2

Factor Description
Variance in Fixed Costs between Treatments
Variance in Variable Costs between Treatments

Factor Levels
1-High, 2-Low
1-High, 2-Low
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Table 4.1.
Cont.
3
4
5

Degree of Volume Discounts
Variance in Patient Volumes between Providers
Variance in Perceived Efficacy between Providers

1-High, 2-Low
1-High, 2-Low
1-High, 2-Low

4.5 Integration Analysis
A total of 320 observations were used to assess model performances under varied
experimental factors. In this section, efficient solutions of the SUD and SSD models are
compared to the optimal treatment protocol solutions generated from total enumeration. First, a
brief discussion of the SSD Heuristic is provided.
4.5.1 SSD heuristic performance. Objective function values of heuristic solutions and
total enumeration solutions are compared to assess the effectiveness of the SSD Heuristic based
on the stated design of experiments. The average execution time for the heuristic was 0.76
seconds. The solutions found using the heuristic were efficient solutions with an average change
in cost of 19% and an average change in efficacy of 3%. Tuning of the heuristic is an
opportunity for future research.
4.5.2 SUD-SSD comparison. Efficient frontier analyses help characterize some
properties of optimal treatment protocols. The efficient frontiers compared used the decision
variable output of each model and assessed it using the supply chain structure. Three measures
were used to assess the performance of the SUD model relative to the SSD: average
improvement in efficacy, average improvement in cost, and average error rate. The average
improvement in efficacy and average improvement in cost are based on the area of opportunity
between the frontier of the SUD and the SSD. No instances of “undefined” behavior were
observed.
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Table 4.2 lists the average performance results of the SUD relative to the SSD by
experimental factor. The most outstanding property shown in comparing model solutions is that
the SSD outperforms the SUD across all performance measures. Also, the SUD tends to perform
closer to the SSD when there is low variance in problem factors. Improvements in efficacy from
the SUD are minimal and appear to have no sensitivity with regard to changes in factor levels.
However, improvements in cost are relatively substantial and do show sensitivity to study
factors. Most of the error in the performance of the SUD is attributed to the difference in total
cost calculations.
Table 4.2
SUD-SSD performance by experimental factor.
Factor Levels
Variance in Fixed Costs between
Treatments
High
Low
Variance in Variable Costs between
Treatments
High
Low
Degree of Volume Discounts
High
Low
Variance in Patient Volumes between
Providers
High
Low
Variance in Perceived Efficacy
between Providers
High
Low

Improvement in
Cost

Improvement in
Efficacy

Average Error
Rate

17%
7%

2%
1%

34%
24%

15%
9%

1%
2%

25%
33%

14%
10%

2%
1%

33%
25%

12%
11%

2%
2%

31%
27%

11%
12%

2%
1%

27%
31%

69
Overall, the average improvement in cost, improvement in efficacy, and error rate are 12%, 2%,
and 29%, respectively. The following sections provide details of performance based on each
experimental factor.
4.5.2.1 Provider variances. The total efficacies for both problems are calculated using the
same factors. Therefore, it can be expected that there is little sensitivity to changes in provider
variances when comparing the SUD and SSD. The average improvement in cost changes
slightly from 12% to 11%, the average improvement in efficacy changes slightly from 1% to 2%,
and the average error rate changes from 31% to 27% as the variance in perceived efficacy
between providers is changed from low to high.
4.5.2.2 Patient volumes. Patient volumes were also used in the formulation of total cost
and total efficacy values. Accordingly, this factor does show an impact on performance that is
similar to the trends in variance in perceived efficacy between providers. The average
improvement in cost is slightly increased from 11% to 12% as variance in patient volumes
between providers is increased. The average improvement in efficacy is unchanged, 2%.
However, the average error rate is increased from 27% to 31% as the variance in this factor is
changed from low to high.
4.5.2.3 Fixed costs. All performance values are increased as the variance in fixed cost
between treatments increased. The average change in cost is increased from 7% to 17%, the
average change in efficacy is increased from 1% to 2%, and the average error rate is increased
from 24% to 34% as variance in this factor is changed from low to high. Analyses of this factor
provide the most support for heightened transparency of treatment costs. Over all factor levels,
the greatest improvement in cost (17%) occurs when the variance in fixed cost between
treatments is classified as high. Efficacy is not directly implied in the calculation of fixed costs

70
as in the case of variable cost (refer to cost factors). Fixed costs are random or unbiased to
treatment efficacies. Without making decisions for treatment selection in lieu of fixed cost,
performance in decreased.
4.5.2.4 Variable costs. Unlike fixed costs, variable costs are related to treatment
efficacies. Therefore, if the efficacy of a treatment increases, the variable cost of the treatment is
also expected to increase. When patient volumes are constant, the efficient frontiers for the SUD
and SSD will make proportionate shifts as shown the first study of this research project.
However, study results show greater improvements in cost (by 6 percentage points) when the
variance in variable costs between treatments is classified as high. Contrarily, the error rate
decreases from 33% to 25% when the factor level is changed from low to high.
4.5.2.5 Volume discounts. The SUD shows better performance across all measures when
the degree of volume discounts is classified as low. The average improvement in cost is
increased from 10% to 14%, the average improvement in efficacy is slightly increased from 1%
to 2%, and the average error rate is increased from 25% to 33% when the system incorporates a
higher level of volume discounts. For this study, a low level to volume discounts corresponds to
a linear relationship between treatment cost and treatment volumes. For a system that desires to
leverage economies of scale, this assumption is impractical. Such a system should expect to see
greater improvements in performance after successful integration for supply chain management.
4.6 Integration Impact
4.6.1 Impact of cost variability. Small SSDs were assessed in preliminary studies to
explore the impact of variable costs, fixed costs, and cost-volume relationships. This section
discusses characteristics in formulary found in a sensitivity analysis of variable cost. The
preliminary study considered a model with three treatments for the six diseases in the
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preliminary model, a total of 729 feasible solutions were generated. The values of si were set at
extremes 0.05 and 10.00 to assess the impact of unit costs as other variables were unchanged.
As a representation of economies of scale, it was assumed that the unit costs were a
function of the square root of the sum of each treatment type times the supply chain cost
coefficient to imply sublinear cost to volume relationships. That is, ui = 0.5 for all i. The
feasible solutions were derived using enumeration. The associated values for total efficacy and
total cost per treatment design solution were then calculated using Microsoft Office Excel 2007.
Figure 4.5 (a) and (b) exhibit the cost versus efficacy of feasible solutions for a system with high
(a)costs,
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region of solutions with
variable costs and low variable
respectively.
high variable costs

1.25

1

0.75

(b) Feasible region of solutions with
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Total Efficacy
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Total Efficacy
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Total Cost
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Figure 4.5. Total cost versus efficacy for (a) high variable cost and (b) low variable cost
solutions.
Upon visual inspection of feasible points, it is possible to notice that solutions with high
variable costs are more segregated. Intuitively, it was assumed that this occurred because the
variances between total costs were higher when unit costs were higher. Another explanation was
provided after viewing the structure of efficient solutions for each cost. As total costs increase,
the product mixes of efficient points in this problem become increasingly diverse. As an
example, consider the three feasible points in the lowest cost region (the far right) of Figure
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4.5(a). Each of these points corresponds to solutions that select only one treatment for each of
the diagnosis in this sample problem. Moving to the next region of points where total costs are an
estimated 33 units, points correspond to selecting one treatment for five diagnoses and another
for the sixth. This pattern of increasing treatment diversity continues through to the region where
total costs are estimated at 44 units. In this final region, each treatment is assigned to exactly
two diagnoses. This pattern in treatment diversity by total costs was not recognized for the low
unit cost solutions or in the case of the SUD where treatment cost have a linear relationship to
treatment volumes.
After observing the pattern in segregation for solutions with high variable costs, the
efficient points for these solutions were further examined. The points forming the efficient
frontier of Figure 4.5 (a) are black and filled to help discern these points from other feasible
solutions. Figure 4.5 (b) illustrates that these points do not form the efficient frontier when
variable costs are low. It is inferred that efficient solutions may not remain efficient as variable
costs are changed. Most of the efficient solutions for the case with high variable cost are not
efficient solutions when variable costs are low and vice versa. However, it is observed that the
efficient solutions in the high efficacy region do remain the same as proposed in the first study of
this research project. It is also observed that the number of solutions changes.
4.7 Chapter Summary
The study discussed in this chapter is unique in modeling and assessing a second study
of integration for healthcare supply chain management. The study examined considers the
implications of supply chain integration in informing treatment cost evaluations. A heuristic is
proposed as a means of understanding system behaviors and the composition of efficient
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treatment selection protocols. It is shown that heightened awareness of treatment costs leads to
better overall system performance.
The final study of integration for this research project will explore the intricacies of
treatment interactions and diagnosis severity levels. In the following study, a genetic algorithm
(GA) is introduced as a solution method for treatment selection protocols of a complex problem.
Properties of SSD efficient solutions are used to develop the GA.
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CHAPTER 5
The Impact of Whole Patient Integration
The primary goal of this chapter is to determine the strategic implications of healthcare
supply chain integration for a decentralized healthcare system that desires minimized cost and
maximized efficacy. A genetic algorithm and a unique comparative analysis technique are also
provided as a means to achieve the primary goal. The study examines a healthcare system before
and after a decision support system enables holistic patient care. A complete design of
experiments is conducted to determine the performance impact of provider variance, varying cost
and efficacy structures, patient severity levels, and demand volumes on treatment selection
protocols. It is determined that low variance between system providers, leveraging economies of
scale, and full patient views (as opposed to per diagnosis) are among factors that lead to greater
system efficiency. Recommendations are made to integrate treatment selection protocols in
order to create more visibility and provide improved, holistic patient care.
5.1 System Segmentation and Integration Opportunity
The final segmentation challenge addressed is that created by the treatment of a patient
by different physicians according to specialty. In considering the impact of integration in this
case, a new representation of efficacy is needed.
5.1.1 Background. Strech et al. (2009) survey studies of physician acceptance of
treatment rationing and find acceptance ranging from 9% to 94%. The study infers that previous
researchers have conducted studies about healthcare coordination in in order to promote
institutional agendas. Strech et al. (2010) discuss the ethics involved in evidence-based
allocation and rationing policies and encourage training, reinforced consistency in decision
making, and increasing transparency as a means to dispel adverse effects on healthcare delivery.
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5.1.2 Characterization. With the whole patient view, treatment design is based on the
patient type rather than a specific disease (where a patient may have one or more). Opportunities
for synergy exist where a treatment might address multiple disease conditions. Risk may occur
when separate physicians suggest treatments which in combination have negative side effects.
As a result, a generalized view of efficacy as a function of treatment amount is constructed. A
generalized view of the relationship between efficacy and utilization for a treatment under the
three forms is given in Figure 5.1.

l1

High

l2

Treatment
Efficacy

l3
Low

Low

Treatment Volume

High

Figure 5.1. Superlinear, linear, and sublinear treatment and efficacies.
One form the treatment and efficacy relationship is assumed to result in a concave shape
between efficacy and utilization as indicated by curve l1. Efficacy has diminishing returns as
treatment increases. In the second form, there is a direct relationship between treatment efficacy
and utilization, implying linearity. In the third and final form, a treatment may provide minimal
efficacy at low levels of utilization but show tremendous gains when approximating full
“dosage”. This form is implied when wil > 1 as indicated by curve l3. (Variable wil is further
defined in section 5.2.2 as a degree of efficacy function curvature.) This representation allows
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consideration of issues of “rationing.” This topic is highly sensitive in the public policy context,
but a key consideration when balancing cost/efficacy impacting policies. When considering the
efficacy assessment for a patient, the severity of their condition should also be considered.
Two policy models are considered. The first models a pre-integration policy of treatment design
based on system efficacy perceptions, system cost consideration, and disease specific /
specialization (SSD model from Chapter 4). The second models a post-integration policy of
treatment design based on system efficacy, system cost consideration, and whole patient
consideration (SSW model). The second model includes representation of treatment volume to
efficacy relationships and consideration of patient type risk/severity.
5.2 Policy Model Formulation
Two policy models are considered. The first models a pre-integration policy of treatment
design based on system efficacy perceptions, system cost consideration, and disease specific /
specialization (SSD model from Chapter 4). The second models a post-integration policy of
treatment design based on system efficacy, system cost consideration, and whole patient
consideration (SSW model). The second model includes representation of treatment volume to
efficacy relationships and consideration of patient type risk/severity.
5.2.1 SSD model (pre-patient integration). With a consensus of treatment efficacy
values, the goal of treatment selection decision makers at the system level is to find the optimal
values of the decision variables xij, the binary decision for all providers in the system to select
treatment i for diagnosis j to maximize the total system efficacy while minimizing total cost.
The cost factors for treatment i are variable cost coefficient si, entry cost coefficient di, the
degree of volume order discounts ui where 0 < ui < 1, and the volume of demand for diagnosis j
Vj.
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Using the same decision variables from Chapter 4, xij, the problem is formally expressed
in SSD model as follows:
max i  j eij xij
min  i  di yi  si


s.t. i xij



(5.1)
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xij  Myi  0  i

(5.4)

xij  0 or 1  i and j

(5.5)

yi  0 or 1  i

(5.6)

j

Note that this model emphasizes the disease independence of the decision-making process.
Decision variables are binary. Patient volume is considered. System cost information is
considered visible by the designer.
5.2.2 SSW model (post-efficacy integration). With consideration for patient types, the
goal of treatment selection decision makers at the system level is to find the optimal values of the
decision variables xil as selected portion of treatment i for patient type l to maximize the total
system efficacy while minimizing total cost. The cost factors for treatment i are the same as in
the SSD. The efficacy factors for this problem are the severity of disease/diagnosis gj, the
severity for patient type Gl, the volume of demand Vl, and the degree of efficacy function
curvature wil.
The SSD model can be modified and simplified into the following form. Maximize the
total system efficacy value and minimize the cost of treatments, subject to the each of the
following constraints:
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A portion of at least one treatment must be utilized for each diagnosis – recall, do nothing
can be a treatment option.



The sum of utilization for treatments must not exceed the capacity (maximum dosage) for a
patient type.



Treatment utilization decisions are normalized to be between zero and one.
Using the decision variables xil, the problem are formally expressed in SSW model as

follows:
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xil  i xil  i and l
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Equation 5.7 is the efficacy objective function. The equation is weighed by the relative patient
type severity and volume in addition to the weight of the individual diagnosis. These weights are
calculated such that the severity of a patient type with multiple diagnoses will be higher than if
the patient were to have a single diagnosis. Additionally, equation 5.7 considers that efficacy
may be nonlinear with respect to a selected treatment volume. A capacity constraint is placed in
the allotted treatment volume to ensure that treatments are not assigned beyond a tolerable
threshold in equation 5.10.
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5.3 Policy Model Solution
SSD policy model solution is shown in Chapter 4. SSW solution is performed by an
enhanced genetic algorithm.
5.3.1 Integrated treatment selection genetic algorithm. The exact solution for SSW is
infeasible due to the complexity and dimensionality of the problem. Therefore, previous models
are studied to capture the essence of practical decision problems that are used to effectively solve
the SSW using the integrated treatment selection genetic algorithm (ITSGA), an iterative
solution procedure. This section discusses the formulation the ITSGA. The discussion is
preceded with an overview of genetic algorithms (GAs) including important terminology and the
use of GAs in efficient frontier analyses.
5.3.1.1 Genetic algorithm overview. The concept of genetic algorithms (GAs) was
developed by Holland in the 1970s. The use of GAs is inspired by Darwin’s theory of evolution
and natural selection. According to natural selection, weaker members of a species will face
extinction. Stronger members are more likely to be selected for reproduction and pass their
genes on to future generations. As the population reproduces, random mutations may occur so
that new genetic traits are presented. If these mutations are advantages, the species evolves to
maintain the new genetic traits.
In artificial systems, a GA is an iterative procedure that uses a current population to
create “children” that make up the next generation for the population. The algorithm selects
“parents” as members from the current population that will contribute their “genes” or
“chromosomes” to their children. According to natural selection, the algorithm usually selects
parents that are strong or have the best “fitness value” among the population. The reproduction
in a GA creates three different types of children for the next generation. “elite children” are the
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members of the current generation that have the best “fitness value” among the population and,
consequently, automatically survive to the next generation. “Crossover children” are created by
combining the genes of a pair of parents. “Mutant children” are created by mutating a single
parent.
The first multi-objective GA was not proposed until 1985 by Schaffer (1985), although
the concept of GAs (Holland, 1975) and Pareto front analyses (Markowitz, 1959) were well
developed beforehand. Since that time, evolutionary algorithms (GAs or derivatives) have
become the most popular heuristic approach to multi-objective optimization problems (Jones,
2002). Konak et al. (2006) provide a thorough tutorial on multi-objective optimization using
optimization and point out the benefits of using GAs in Pareto front analyses.
There are many other studies that introduce or compare performance of varying multiobjective optimization GAs (Coello, 1999; Fonseca and Fleming, 1998; Jensen, 2003; Xiujuan
and Zhongke, 2004; Zitler and Thiele, 1999). Parameter tuning for GAs has been given
extensive research (Villegas et al., 2006; Medaglia et al., 2009; Zandieh and Karimi, 2011). The
Niched Pareto Genetic Algorithm (Horn and Goldberg, 1994), Nondominated Sorting Genetic
Algorithm (NSGA) (Srinivas, N. and Deb, 1994), Fast Non-dominated Sorting Genetic
Algorithm (NSGA-II) (Deb et al., 2002), Strength Pareto Evolutionary Algorithm (SPEA)
(Zitzler, E. and Thiele, 1999), Pareto-Archived Evolution Strategy (PAES) (Knowles and Corne,
2000) are among the more common GAs for multi-objective optimization.
Early versions of multi-objective GAs do not include considerations for problem
constraints. Anagnostopoulos and Mamanis (2009) conclude that the SPEA, PAES, and NSGAII
all perform well for multi-objective portfolio selection problems with or without constraints.
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The aim of this research is not to provide a comparison of varying GAs or to develop a
methodology for GA parameter tuning. However, this study does survey the structures of
popular multi-objective, multi-constraint optimization GAs that have been applied to Pareto front
analyses in order to establish parameters for the ITSGA discussed in Section
Table 5.1 summarizes a survey of GA parameters used in ten relevant studies. Each of
the listed studies applies a GA to a multi-objective optimization problem that has multiple
constraints. The majority of the studies are for bi-objective problems. With the exception of
Prakash et al. (2012), Anagnostopoulos and Mamanis (2011), Bowman et al. (2010) and Ko and
Wang (2010), the studies have binary decision variables. Bowman et al. (2010), Goyal (2011),
and Vlah Jeric and Figueria (2012) have 5, 24, and 4 objectives, respectively.
A variation of schemes is used to set population sizes. Many aim at setting the
population size relative to the number of decisions or objectives. Prakash et al. (2012) propose a
knowledge-based genetic algorithm (KBGA) that selects alternates between various crossover
and mutation operators as the system acquires knew knowledge.
Single point crossover operators are used where gene member represent a set of resources
such as surgical suites or time shifts for labor (Bowman et al., 2010; Medaglia et al. ,2009, and
Gul et al., 2011). Single point crossover operators swap portions of parent genes at a single
point. Other studies apply uniform operators that all the combination or switching of gene
members among parents with equal probability in order to form crossover children
Anagnostopoulos and Mamanis (2011), Goyal (2011), Alves, M. Almeida (2007), Ko and Wang
(2010).

Table 5.1
GA parameters in applied multi-objective, multi-criteria optimization problems.
Reference

Number of
objectives

Population
size

Selection
strategy

Crossover operator
(rate)

Mutation
rate

Elite
children

Generations

Alves, M. Almeida (2007)

2,3,4

150, 350

Tournament

Uniform (80%)

10%

N/A

20× (2×#Objs+1)

Anagnostopoulos and Mamanis (2011)

2

500

Tournament

Uniform (100%)

10%

N/A

500

Bowman et al. (2010)

5

64×#Objs

Tournament

Single point (70%)

1/N

50%

100

Goyal (2011)

24

200

Tournament

Uniform (70%)

5%

N/A

500

2

40

Tournament

Single point (90%)

1/N

25%

50

2

20, 70

Roulette

Uniform (90%)

1/N

N/A

200,500

*

Gul et al. (2011)

Ko and Wang (2010)
*

Medaglia et al. (2009)

2

50

Tournament

Single point (70%)

5%

N/A

100

*

Pato and Moz (2000)

2

400

Tournament

PMX (60%)

0.10%

2

≤ 2000

Prakash et al. (2012)

2

Custom

Custom

Custom

Custom

N/A

Custom

Vlah Jeric and Figueira (2012)

4

50

Tournament

XVRA (90%)

10%

N/A

N/A

ǂ

*
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Mutation rates are set low across all studies in the literature, varying between 5% of the
population size, 10% of the population size, and 1/N where N is the number of variables in a
problem. More recently, multi-objective GAs have employed elitism strategies and proven to
outperform traditional GAs that neglect elitism. Three of the listed studies employ elitism using
one of two strategies: (1) maintaining elite children in the population throughout the generations
(Pato and Moz, 2000) or (2) storing elite solutions in an external archive and reintroducing the
elites to the population (Bowman et al., 2010 and Gul et al. 2011). The second strategy
maintains a population that is usually 25 – 50% of the desired population size and therefore
requires more memory and execution time. The number of generations range from 50 to 2000.
5.3.1.2 ITSGA methodology. The ITSGA is implemented using the multi-objective
optimization functionality of the Matlab 7.12.0 (R2001a) GA toolbox. The following outline
summarizes how the ITSGA works:
0. A user inputs population size P, termination condition X, and GA parameters e%, c%, and
p%.
1. The algorithm begins by creating an initial population. Each gene in a population henceforth
is the length of the number of variables in the SSW. Position T×(l - 1) + i, in a gene takes the
value of xil where T is the number of treatments in the SSW. The initial population is often
created at random in GAs. The specific initial population generation used in this study is
detailed later in this section.
2. The algorithm creates a sequence of new populations. At each step, the algorithm uses the
individuals of the current generation to create the next population. The create the new
population, the algorithm performs the following steps:
a. Scores each member of the population by computing its fitness value.
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b. Scales the raw fitness scores to convert them into a more usable range of values.
c. Selects members called “parents” based on their fitness values.
d. Performs an elitist reproduction strategy on P×e% members where e% of the best
individuals (individuals with the best fitness values) in the current population are passed
on to the next generation.
e. Produces (100% - e%)×P×c% crossover children by tournament selection. The
tournament selection method is used to select parents for crossover children. The
scattered crossover operator is used in this study and detailed in the next section
f. Produces (100% - c%)×(100% - e%)×P mutant children. In mutation, a child is produced
by making random changes to a single parent. The specific mutation operator used in this
study is detailed in the next section.
g. Replaces current population with the next generation.
3. The algorithm stops when termination condition X is met.
To generate the initial population, the concept of low cost and high efficacy regions as
discussed in Chapter 3 is applied to help ensure that GA generates a frontier that covers the full
range of the actual frontier and possibly contains 0-1 solutions where they are desired. With
regard to the properties of efficient solutions in the low cost region of the efficient frontier, The
ITSGA considers PC individuals of the initial population as solutions in the low cost region of
the feasible solution set. The GA estimates the cost of treatment i as
Ci = (di +si (∑l Vi )ui )⁄(∑l Vi ). The value of mini ( Ci ⁄∑i Ci ) decreases as the range of treatment
costs increases. Additionally, efficient points tend to be more segregated with fewer points
within the low cost region as the range in treatment costs increases. Based on this tendency, the
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ITSGA sets xal = 1 and xi≠a,l = 0 for all l where Ca ⁄∑i Ci = mini ( Ci ⁄∑i Ci ). The value
PC =⌊mini (𝐶𝑖 ⁄∑𝑖 𝐶𝑖 )⌋×P.
With regard to the properties of efficient solutions in the low cost region of the efficient
frontier, The ITSGA considers PE individuals of the initial population as solutions in the low cost
region of the feasible solution set. The GA estimates the efficacy of treatment i as Ei =
maxi ( ∑j eij ⁄∑i ∑j eij ). The value of maxi ( Ei ⁄∑i Ei ) increases as the range of treatment efficacy
increases. Additionally, efficient points tend to be more segregated, with fewer points within the
high efficacy region, as the range in treatment efficacies increases. To avoid overlap with the
members assigned to the low cost region, the number of candidates accepted as initial solutions
in the high efficacy region is as follows:










  min i Ei /  i Ei   P, PC  min i Ei /  i Ei   P  P
PE   
otherwise.

 P  PC ,

(5.14)

Based on this tendencies of efficient solutions of the high efficacy region, the ITSGA sets
xbl = 1 and xi≠b,l = 0 for all l where Eb ⁄∑i Ei = maxi ( Ei ⁄∑i Ei ) for PE members of the initial
population. For the genes of any individual not assigned as a solution in the low cost region or
high efficacy region of the initial feasible solution set, the ITSGA randomly assign values such
that ∑i xil = 1 and xil = [0, 1].
As suggested, crossover children are created using the tournament selection strategy. The
tournament proportion is p%. Therefore, P×p% genes are selected at random from the
population and the individual with the best fitness value is selected as a parent. The scattered
crossover strategy is used. For scatter crossover, a random binary vector is created. The vector
is used to select genes from the first parent where 1s are present. Otherwise, genes are selected
from the second parent.
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A custom mutation operator is used to ensure diversity and discourage convergence to a
small region. For 50% of mutant children, gene elements are randomly set to 0 for each l. For
another 25% of mutant children, genes are unchanged. For the remaining mutant children, gene
elements are set to Σj∈l (gleij)/Σj∈lgl for each element corresponding to xil so that greater utility is
assigned to a diagnosis with high efficacy and high severity values.
5.3.1.3 ITSGA parameters. The GA parameters used in this study are set according to
suggestions made in literature in order to ensure the quality and timeliness of the ITSGA. In
accordance to the Bowman et al. (2010) study, the population size for this study is set to 64 times
the number of objectives. Stall generation limit is 100 to ensure that the GA terminates when
there is no improvement in the objective function for a sequence of consecutive generations of
length stall generations. This study also employs the more common tournament selection
strategy. The crossover rate is set to 0.8 and the Matlab crossover heuristic operator is used with
a weight of 1.2. The remainder of the population undergoes the custom mutation operator.
Mutation occurs at a low rate as suggested in most literature. This study employs a 0.2 mutation
rate (1 – crossover rate) using a custom mutation operator. For more detail on the Matlab
crossover heuristic or other default values and operators, the reader is referred to the Genetic
Algorithm and Direct Search Toolbox (2004). The parameters used for the ITSGA in this study
are summarized as follows:


Population Size = 128



Initial Population = Custom



Elite Count = 2



Selection = Tournament



Crossover Fraction = 0.8
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Crossover Operator = Matlab crossoverheuristic



Mutation Operator = Custom



Stall Generation Limit = 500

5.4 Integration Assessment
5.4.1 Selected factors. Based on the characterization in Section 4.1, the following
factors are considered in developing a design of experiments.
5.4.1.1 Patient volume factors. For each problem, the demand volume of patients with
disease j serviced by each provider k, Vjk, must be known. The variability in Vjk is one factor
considered in the model. High variability indicates presence of treatment design by both experts
and inexperienced providers. Low variability indicates that patient volumes are balanced across
designers. As patient types are defined by disease combinations, the demand volume of patient
type l is defined as Vlk = ∑j∈l Vjk .
5.4.1.2 Efficacy factors. The parameters used to evaluate efficacy values in this study
are eijk, and Vlk. The basis for evaluating total efficacy between problems is that the perceived
efficacy may differ between providers and true efficacy may be estimated based on provider
expertise. Values of efficacy are normalized to range from 0 to 1 with 0 being ineffective and 1
being completely effective. Given that provider k’s perceived efficacy of treatment i for
diagnosis j is eijk, the system calculated efficacy according to ẽij = (∑k Vjk ẽij )⁄(∑k Vjk ). The
variability in perceived efficacy is a factor in the design of experiments. High variability
indicates many different perceptions regarding treatment efficacy. Low variability indicates
some consensus in terms of efficacy. Four levels are used for the efficacy curve shape:
superlinear where wil = 2, linear where wil = 1 and sublinear where wil = 0.5. The fourth level
includes a random mix of shapes.
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There are two variables considered for severity, the severity of an independent diagnosis,
gj, and the severity of a patient group, Gl. The value of gj ranges from 1 to 10 with 1 being the
lowest and 10 being the highest level of severity. The severity values of Gl follow the same
ranking scale and have the following relationship to gj:

Gl 

10 x   jl 10  g j 
10 x 1

(5.15)

The factor has two levels based on the variability in patient condition severity.
5.4.1.3 Cost factors. The parameters used to generate cost values in this research are di
and ai. The parameters for fixed costs and variable cost coefficients are varied from 0 to 100 and
then added to form a unit cost. It is assumed that the variable cost of treatment i tends to be
directly related to the relative efficacy of treatment i. Understanding that not all variable cost are
correlated to treatment efficacies, a “noise” factor is added such that the variable cost of
treatment i is si = ai ( ∑j ẽij )/( ∑j ẽij ) ± σi . The cost of selecting treatment i is calculated as ci =
u

di yi +si ( ∑j Vj xij ) i . Variability in fixed costs and variability in variable costs are factors in the
design of experiments.
5.4.2 Design of experiments. The objective of the experimental design is to understand
the relationship between parameters (variance in fixed cost, variance in provider’s perceived
efficacy, variance in disease severity, variance in variable cost coefficient, degree of volume
discounts, variance in provider’s patient volumes, and degree of efficacy curvature) on the
performance of treatment selection protocols of the SSD in comparison to the SSW. This study
does not intend to conduct an exhaustive study for parameter tuning. Parameters are set in a
manner that allows for broad yet critical inferences to be made relative to a system evolving
through the four policies of treatment protocols selection.
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5.4.2.1 Generation of problem instances. In this study, a problem with three treatments,
three providers, and three diagnoses (which implies seven patient types) is examined. There are
seven parameters used to generate the four problems in this research. These parameters are
generated using custom programs in Matlab 7.12.0 (R2011a).
5.4.2.2 Random value generation. The values for di, eijk, gj, ai, and Vlk, are randomly
generated from beta distributions as described in Chapter 3. The Matlab code for each of the
random number generators is found in the APPENDIX. The problem parameters varied as a part
of this research are summarized in Table 5.2. Ten replications are executed for each factor level
combination in the design for a total of 2560 observations.
Table 5.2
Study 3 experimental problem factors and levels.
Factor
1
2
3
4
5
6
7

Factor Description
Variance in fixed cost
Variance in provider’s perceived efficacy
Variance in disease severity
Variance in variable cost coefficient
Degree of volume discounts
Variance in provider’s patient volumes
Degree of efficacy curvature

Factor Levels
1-High, 2-Low
1-High, 2-Low
1-High, 2-Low
1-High, 2-Low
1-Concave, 2-Linear
1-High, 2-Low
1-Concave, 2-Linear, 3-Convex, 4-Random

5.5 Integration Analysis
A total of 2560 experiments were used to assess model performances under varied
experimental factors. In this section, efficient solutions SSD models are compared to the optimal
treatment protocol solutions generated from the ITSGA for the SSW model. First, a brief
discussion of the performance of the ITSGA is provided.
5.5.1 ITSGA performance. The performance of the ITSGA is assessed based on the
average distance between generational fitness values, termination condition, number of efficient
solutions determined, number of generations required to terminate, spread, and run time. The
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ITSGA always terminated due to a convergence to a relatively low difference between fitness
values. The number of generations required to terminate ranged from 502 to 865 with a median
of 502. The median run time was 69 seconds with a maximum of 118 seconds. The median
distance and spread were 0.01 and 0.44, respectively. The median number of efficient solutions
found by the ITSGA is 4 with the highest value of 120.
5.5.2 SSD-SSW comparison. Efficient frontier analyses are used to compare the
performance of the problems generated help characterize some properties of optimal treatment
protocols. For this analysis, solutions of the SSD were found using total enumeration and
solutions of the SSW were estimated using the ITSGA.
A few steps were taken to transform the solutions of the SSD for comparison to the SSW.
Recall that SSD solutions are represented as xij and take on binary values. In the instance where
a patient group l contained diagnosis j and xij equaled one, the corresponding xil was set to one
for treatment i. Otherwise, xil was set to zero for treatment i. Afterwards, the transformed
variable was substituted into the objective function for the SSW to find the comparable objective
function value.
Three measures were used to assess the performance of the SSD model relative to the
SSW: average improvement in efficacy, average improvement in cost, and average error rate.
The average improvement in efficacy and average improvement in cost are based on the area of
opportunity between the frontier of the SSD and the SSW.
Table 5.3 lists the average performance results of the SSD relative to the SSW by
experimental factor. The most outstanding property shown in comparing model solutions the
SSW outperforms the SUD across all performance measures. Also, the SUD tends to perform
closer to the SSD when there is low variance in problem factors, with the exception variable cost
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between treatments. Improvements in efficacy from the SUD are minimal and appear to have
little sensitivity with regard to changes in factor levels. However, improvements in cost are
relatively substantial and do show sensitivity to most study factors. Most of the error in the
performance of the SUD is attributed to the difference in total cost evaluation. Overall, the
average improvement in cost, improvement in efficacy, and error rate are 17%, 3%, and 47%,
respectively.
Table 5.3
Average performance results of the SSD relative to the SSW by experimental factor.
Factor Levels
Variance in Perceived
Efficacy between Providers
High
Low
Variance in Patient Volumes
between Providers
High
Low
Variance in Fixed Costs
between Treatments
High
Low
Variance in Variable Costs
between Treatments
High
Low
Volume Discounts
High
Low
Variance in Severity Between
Diseases
High
Low
Efficacy Curvature
Concave
Linear
Convex
Random

Improvement
in Cost

Improvement
in Efficacy

Average Error
Rate

Undefined for
Cost

Undefined for
Efficacy

17%
17%

3%
3%

47%
47%

3.2%
5.2%

3.1%
4.7%

17%
17%

3%
3%

47%
47%

4.7%
3.8%

4.5%
3.3%

17%
17%

3%
3%

47%
47%

4.2%
4.2%

3.8%
4.1%

19%
15%

2%
4%

48%
46%

2.1%
6.3%

1.6%
6.2%

13%
21%

2%
4%

43%
51%

5.5%
3.0%

4.8%
3.0%

18%
16%

4%
3%

48%
46%

4.3%
4.1%

4.0%
3.8%

20%
10%
10%
27%

3%
1%
2%
6%

62%
35%
33%
59%

3.6%
4.2%
4.7%
4.4%

3.6%
4.2%
4.7%
3.1%
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5.5.2.1 Provider variances. The results indicate that the performance of the SSD is not
sensitive to the variance in perceived efficacy between providers. This outcome is intuitive
because the efficacy variable for both problems is the same. However, the methods to evaluate
the total efficacy for each problem differ. It is expected that performance will be sensitive to
variables that differ between the two problems (i.e. variance in severity between diseases and
degree of efficacy curvature). Across both levels of this factor, the average improvement in cost,
improvement in efficacy, and error rate are the same as the overall values: 17%, 3%, and 47%.
5.5.2.2 Patient volumes. It was expected that there would be sensitivity to this factor,
based on study 2 of cost integration. In the second study, there is a negligible increase for the
average improvement in cost, average improvement in efficacy, and average error rate. The
same is shown in this study. The average improvement in cost, improvement in efficacy, and
error rate are 17%, 3%, and 47%, respectively, regardless of the factor level.
5.5.2.3 Fixed costs. The total fixed costs for both problems are calculated using the same
factors. Therefore, it can be expected that there is little sensitivity to changes in fixed cost when
comparing the SSD and SSW. The average improvement in cost, improvement in efficacy, and
error rate are 17%, 3%, and 47% respectively.
5.5.2.4 Variable costs. Unlike fixed costs, variable costs are related to treatment
efficacies. Therefore, if the efficacy of a treatment increases, the variable cost of the treatment is
also expected to increase. When patient volumes are constant, the efficient frontiers for the SSD
and SSW will make proportionate shifts as shown the first study of this research project.
However, study results show greater improvements in cost (by 4 percentage points) when the
variance in variable costs between treatments is classified as high. The average error rate
increases slightly from 46% to 48% when variance in variable cost changes from low to high.
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Contrarily, the average improvement in efficacy decreases slightly by 2 percentage points. To
determine the cause for this decreased performance, the number of qualifying comparisons was
evaluated. In the instances where the efficient frontiers for cost or efficacy do not lie within the
same regions for integration frontiers are not compared improvements in cost or efficacy are
considered undefined. The percentage in undefined comparisons for cost and efficacy is 6% and
2%, respectively, when the variance in the variable cost is low and high, a difference of 4
percentage points. This phenomenon implies that the ranges of cost and efficacy for the SSW
are so far improved over the SSD that to two problems are more often incompatible when the
variance in variable costs is low. Across all other factors, the average difference in the lowest
and highest percentage of undefined comparisons is only 0.4 percentage points.
5.5.2.5 Volume discounts. The SSW outperforms the SSD across all measures and factor
levels for volume discounts but the greatest improvement occurs when the degree of volume
discounts is classified as low. The average improvement in cost is increased from 13% to 21%,
the average improvement in efficacy is slightly increased from 2% to 4%, and the average error
rate is increased from 43% to 51% when the system incorporates a lower level of volume
discounts.
As discuss with variable costs, it was initially expected that the improvement at lower
levels of discounts occurred because of undefined comparisons. However, for this factor, the
number of undefined comparisons is higher when volume discounts are high, by 2.5 and 1.8
percentage points for cost and efficacy, respectively. Upon further exploration of this factor, it
was found that 192 of 1210 defined comparisons (16%) with high volume discounts have onepoint solutions where only 70 of 1242 defined comparisons (6%) with low volume discounts
result in one-point solutions. This phenomenon indicates that there are more instances where the
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system will select only one efficient treatment protocol when volume discounts are high. This
conclusion confirms concepts presented in Section 3.3.1. As variable costs are increased due to
volume discounts, the number of efficient points along an efficient frontier are decreased. Since
there are fewer efficient solutions to pick from when volume discounts are high, it is more likely
that efficient solutions are matched between the SSD and SSW.
5.5.2.6 Disease severity. The SSW shows greater improvement over the SSD for all
measures when the variance in severity between diseases is classified as high. The average
improvement in cost increases from 16% to 18%, the average improvement in efficacy increases
from 3% to 4%, and the average error rate increases from 46% to 48% as the variance in severity
between diseases changes from low to high. As previously mentioned, the SSD does not account
for this factor. The SSW model is better informed and, therefore, can better manage system
variance for this factor.
5.5.2.7 Efficacy curvature. Recall that concave efficacy curvature indicates that a
treatment provides the greatest improvement in efficacy at low utility values. Therefore, minor
changes for from low treatment utilities can result in larger changes in efficacy than otherwise.
The results from this study indicate that the SSW has high improvement over the SSD when the
efficacy curvature is classified as concave. The performance of the SSW is even higher when
the curvature is random or a mixture of concave, linear, and convex. Over all of the factors in
this analysis, improvements in cost efficacy are more prevalent in the SSW when efficacy
curvature is random.
5.6 Integration Impact
There are many practical implications granted from the outcomes of this research. From
the onset of this research, there were no assumptions about how a random relationship between
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efficacy and volume may impact performance. It is understood that the relationship between
treatment efficacy and treatment volumes can be more random than linear, concave, or convex
and definitely vary between patient types in practice. The results support integration regardless
of efficacy and volume relationships. However, it is shown that high performance gains exists
for a system that experiences this type of random efficacy relationship. This outcome has
promising implications for integration where treatment efficacies are more complex.
Studies in Chapters 3 and 4 show how the impact of integration can change with varying
levels of perceived efficacy, patient volume, and fixed costs. Although the factor level impact is
not shown here, given the progressive development of integration policies, previous outcomes
are still implied here. This study advances those findings to exhibit integration advantages in a
system that is much more complex than the IUD and SUD, as well as the SSD.
Here the use of evidence-based policies reinforces consistency in decision making such
that cost and efficacy become more optimal. Strech et al. (2010) supports this finding. In
general, regardless of factor levels, this study supports integration toward having a full view of
patients across the system. It is further illustrated in the instances of high variance in variable
costs as well as disease severities; consolidated and data-driven decision making processes lead
to better performance than otherwise. This is particularly insightful and useful to an agency like
the DLA that supports a system where the diagnoses of patients can range from minimal to fatal
requiring supplies as inexpensive as a small bandage to capital expenditures like CT scan
machines. Given the complexities of the defense healthcare system, study outcomes support
efficacy integration.

96
5.7 Chapter Summary
The study discussed in this chapter is unique in modeling and assessing a third study of
integration for healthcare supply chain management. The study examined considers the
implications of a more holistic approach to patient care where visibility can inform cost and
efficacy. A custom GA is proposed as a solution technique to the more complex problem of
treatment protocol selection. Many of the premises noted in previous chapters are confirmed,
illustrating that integration can improve of overall efficiency for simple and complex system
structures.
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CHAPTER 6
Conclusions and Future Research
6.1 Research Summary
Based on existing gaps in healthcare treatment selection protocols or the lack of, it was
expected from the onset of this dissertation research that decision support system integration can
improve healthcare systems performance. This research accessed various systems factors that
can impact treatment selection performance in order to determine how modifying behaviors can
improve efficiency. Specifically, physician bias, patient volumes, leveraging economies of scale
or costing structures, and complex treatment efficacy calculations were evaluated by modeling
three studies of integration. The results indicate that more integrated treatment selection
protocols lead to decreases in cost alongside increases in efficacy. Additionally, this dissertation
explained how more complex healthcare systems or systems with higher variability in
performance factors have the highest opportunity for improvement.
Chapter 2 of this research explains provider integration where shared decision making is
enabled among physicians to mitigate physician bias and exploit physician expertise. This form
of integration can lead to greater cost improvements for systems with higher variance in perceive
treatment efficacies between physicians. It has been previously determined that evidence based
treatment selection protocols lead to improved efficacies but this study extends to illustrate how
evidence based treatment selection also improves costs. Enabling cost awareness and consensus
among providers on best practices can ensure that the most effective treatments are selected for a
given cost.
Cost improvements are also greater in instances of high variance in patient volumes
between providers. There are a few factors that influenced this outcome. The first study of

98
integration models system costs without regard for entry costs. Therefore, the system is less
likely to avoid incurring entry costs in selecting treatments. This behavior led to lower
performance where the variances in fixed costs between treatments were highest. In determining
system efficacy values, there is also value added in weighing provider opinions based on the
volume of patients treated for a particular diagnosis or diagnoses. Providers with relatively little
experience in treating a diagnosis will have less influence on system efficiency as they encounter
fewer patients. This aligns with practices of the Veterans Affairs (VA) Health Care system that
incentivizes specialized care. Counter to this VA practice, newer legislation from the Affordable
Care Act encourages civilian healthcare providers to become more inclusive and provide more
generalized patient treatment. It is expected that generalized patient care will centralize practices
so that patients can avoid transferring and issues associated with transferring between providers
(such as incomplete transfers of patient medical history, returns, and travel cost). In either
system, with specialized or generalized care, providing consensus for treatment efficacy can
improve overall efficacy as well as cost.
Chapter 3 discusses cost integration. The study in this chapter extends on observations
in Chapter 2 to explore the impact of leveraging economies of scale or exploiting opportunities
for volume discounts. It is found that sub linear relationships between volume and cost (such
that incremental costs decrease as patient demand volumes increase) encourage decision makers
to avoid entry costs. As higher entry costs are most avoided, integration allows greatest cost
improvements where the variance in fixed costs between treatments is high. Cost are also greatly
improved in instances with high variance in variable cost between treatments. In systems with
limited visibility, providers are not fully capable of recognizing opportunities for discounted cost
where treatments have higher patient demands. Whereas, an integrated system can aid providers
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in trending patient volumes and negotiating costs with suppliers. Overall, cost and efficacy is
improved when treatment selection protocols consider volume discounts.
For the final study, discussed in Chapter 4, treatment selection behaviors of
aforementioned chapters were incorporated in customized a genetic algorithm to solve the more
complex treatment selection problem. Namely, the observation that providers with greater
treatment volumes will have more influence on selection and that efficient treatment selections
tend to avoid entry costs. The final model observed in this study extends on the previously
studies MOOPs to account for a more complex treatment efficacy calculation. The observed
treatment efficacy structures encourage the use of decision support systems with advance
analytics especially where treatment efficacy and volumes random or super linear. The random
relationship led to the highest improvements in cost and efficacy upon enhanced integration as
treatment efficacies where now selected in a more informed manner. The super linear
relationship led to the second highest improvements in cost and also had an impact on how
selection decisions change with volume discounts. Treatment selection in instances with low
volume discounts outperformed systems with high volume discounts for cost and efficacy (by
eight and two percentage points, respectively). This phenomenon occurs according to a concept
presented in Section 3.3.1. As variable costs are increased due to volume discounts, the number
of efficient points along an efficient frontier are decreased. Since there are fewer efficient
solutions to pick from when volume discounts are high, it is more likely that efficient solutions
are matched.
6.2 Research Contributions
In all, this research provides contributions to industrial and systems engineering that can
be adapted for various applications although the research focuses on healthcare and the design of
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treatment selection protocols. Strategies for efficient treatment selection protocols and system
evolution are investigated. Definition is provided for key parameters to model treatment
protocols under varying operational strategies along with defining three key types of integration
for holistic patient care. A novel comparative analysis method is employed to measure the
impact of multi-objective decision making. Custom heuristics, including a genetic algorithm, are
developed to solve for complex treatment selection problems.
6.3 Future Research
The three studies explored through chapters 2, 3, and 4 of this dissertation provide
evidence in support of centralized or shared decision making in medical treatment protocol
selection. Future research will provide evidence of system behaviors based on supply chain
operations outside of the healthcare industry. In addition to applying real data, future studies
will attempt to improve optimization routines and survey integration teams for best practices.
The results of this study will be extended to create a requirements analysis for a supporting
information technology infrastructure.
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Appendix
Procedures to Generate Problem Parameters
function [eijk,eij,ci] = ...
study1_Coefficients(number_of_treatments, number_of_diseases,...
number_of_providers, design)
% The number of all possible patient types is generated
number_of_patient_types = 0;
for j=1:number_of_diseases
number_of_patient_types = number_of_patient_types + ...
factorial(number_of_diseases)/(factorial(number_of_diseases-j)...
*factorial(j));
end
%% --------------------------- Parameters --------------------------------% This section of code defines and initiates values of all parameters. The
% following functions generate appropriate random values for parameters
% based on parameter indices and level in the design of the experiment.
% ------------------------------------------------------------------------% di fixed cost for selecting treatment i
di = generate_di(number_of_treatments, design(2));
% eijk
the perceived value of efficacy for treatment i for diagnosis j...
% by provider k
eijk = generate_eijk(number_of_treatments, number_of_diseases,...
number_of_providers, design(3));
% vlk
volume of patients group l by provider k
vlk = generate_vlk(number_of_patient_types,...
number_of_providers, design(5));
%% ------------------------ End Parameters -------------------------------%% ---------------------- Dependent Variables ----------------------------% This section of code defines and initiates values that are dependent on
% the problem parameters based on parameter indices.
% ------------------------------------------------------------------------%Volume of patient groups
% vjk volume of patient with disease j for provider k
vjk = zeros(number_of_diseases, number_of_providers);
for k = 1:number_of_providers
vjk(:,k)=diseasecombos(number_of_diseases,vlk(:,k));
end
%vk volume of patients per provider
vk = sum(vjk,1);
%Evidence based efficacy
% eij estimated efficacy for treatment i and diagnosis j
eij=zeros(number_of_treatments,number_of_diseases);
for i = 1: number_of_treatments
for j = 1:number_of_diseases
for k = 1:number_of_providers
eij(i,j)=eij(i,j)+vjk(j,k)*eijk(i,j,k);
end
x=sum(vjk,2);
eij(i,j)=eij(i,j)/x(j);
end
end
%Efficacy related cost coefficient
% si efficacy related variable cost coefficient for treatment i
si = generate_si(eij,number_of_treatments, design(4));
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%Unit cost coefficient without consideration for volume or discounts
ci = di + si;
%% -------------------- End Dependent Variables --------------------------function [ui,vj,eij,di,si] = ...
study2_Coefficients(number_of_treatments, number_of_diseases,...
number_of_providers, design)

number_of_patient_types = 0;
for j=1:number_of_diseases
number_of_patient_types = number_of_patient_types + ...
factorial(number_of_diseases)/(factorial(number_of_diseases-j)...
*factorial(j));
end
%% --------------------------- Parameters --------------------------------% This section of code defines and initiates values of all parameters
% ------------------------------------------------------------------------% di fixed cost for selecting treatment i
di = generate_di(number_of_treatments, design(2));
% eijk
the perceived value of efficacy for treatment i for diagnosis j...
% by provider k
eijk = generate_eijk(number_of_treatments, number_of_diseases,...
number_of_providers, design(3));
% ui
degree of volume discount for the cost of treatment i
ui = generate_ui(number_of_treatments, design(5));
% vlk
volume of patients group l by provider k
vlk = generate_vlk(number_of_patient_types,...
number_of_providers, design(6));
%% ------------------------ End Parameters -------------------------------%% ---------------------- Dependent Variables ----------------------------% This section of code defines and initiates values that are dependent on
% the problem parameters
% ------------------------------------------------------------------------%Volume of patient groups
% vjk volume of patient with disease j for provider k
vjk = zeros(number_of_diseases, number_of_providers);
for k = 1:number_of_providers
vjk(:,k)=diseasecombos(number_of_diseases,vlk(:,k));
end
vj = sum(vjk,2);
%Evidence based efficacy
% eij estimated efficacy for treatment i and diagnosis j
eij=zeros(number_of_treatments,number_of_diseases);
for i = 1: number_of_treatments
for j = 1:number_of_diseases
for k = 1:number_of_providers
eij(i,j)=eij(i,j)+vjk(j,k)*eijk(i,j,k);
end
x=sum(vjk,2);
eij(i,j)=eij(i,j)/x(j);
end
end
%Efficacy related cost coefficient
% si efficacy related variable cost coefficient for treatment i
si = generate_si(eij,number_of_treatments, design(4));
%% -------------------- End Dependent Variables ---------------------------
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function [eijk,gj,ui,vlk,wil,vjk,eij,ci,di,si,Gl,d] = ...
study3_Coefficients(number_of_treatments, number_of_diseases,...
number_of_providers, design)
number_of_patient_types = 0;
for j=1:number_of_diseases
number_of_patient_types = number_of_patient_types + ...
factorial(number_of_diseases)/(factorial(number_of_diseases-j)...
*factorial(j));
end
%% --------------------------- Parameters --------------------------------% This section of code defines and initiates values of all parameters
% ------------------------------------------------------------------------% di fixed cost for selecting treatment i
di = generate_di(number_of_treatments, design(2));
% eijk
the perceived value of efficacy for treatment i for diagnosis j...
% by provider k
eijk = generate_eijk(number_of_treatments, number_of_diseases,...
number_of_providers, design(3));
% gj
severity diagnosis j for patient group
gj = generate_gj(number_of_diseases, design(4));
% ui
degree of supply chain cost function for treatment i
ui = generate_ui(number_of_treatments, design(6));
% vlk
volume of patients group l by provider k
vlk = generate_vlk(number_of_patient_types,...
number_of_providers, design(7));
% wil
degree of efficacy function treatment i for patient group l
wil = generate_wil(number_of_treatments,...
number_of_patient_types, design(8));
%% ------------------------ End Parameters -------------------------------%% ---------------------- Dependent Variables ----------------------------% This section of code defines and initiates values that are dependent on
% the problem parameters
% ------------------------------------------------------------------------%Volume of patient groups
% vjk volume of patient with disease j for provider k
vjk = zeros(number_of_diseases, number_of_providers);
for k = 1:number_of_providers
vjk(:,k)=diseasecombos(number_of_diseases,vlk(:,k));
end
%Evidence based efficacy
% eij estimated efficacy for treatment i and diagnosis j
eij=zeros(number_of_treatments,number_of_diseases);
for i = 1: number_of_treatments
for j = 1:number_of_diseases
for k = 1:number_of_providers
eij(i,j)=eij(i,j)+vjk(j,k)*eijk(i,j,k);
end
x=sum(vjk,2);
eij(i,j)=eij(i,j)/x(j);
end
end

%Efficacy related cost coefficient
% si efficacy related variable cost coefficient for treatment i
si = generate_si(eij,number_of_treatments, design(5));
ci = di + si;
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%Patient groups and severity
Gl=ones(number_of_patient_types,1);
d=zeros(number_of_patient_types,number_of_diseases);
r=0;
for j=1:number_of_diseases
A=combinator(number_of_diseases,j,'c');
[rows,columns]=size(A);
for l=1:factorial(number_of_diseases)/...
(factorial(number_of_diseases-j)*factorial(j))
for m=1:rows
for k=1:columns
d(r+m,k)=A(m,k);
end
end
end
A=[];
r=r+rows;
end
countjl=zeros(number_of_diseases,number_of_patient_types);
for l=1:number_of_patient_types
for j=1:number_of_diseases
if find(d(l,:)==j)>0
Gl(l) = Gl(l)*(10-gj(j));
countjl(j,l)=1;
end
end
x=sum(countjl,1);
Gl(l) = (10^x(l)-Gl(l))/(10^(x(l)-1));
end
%% -------------------- End Dependent Variables --------------------------function di = generate_di(number_of_treatments, factor_level)
di = zeros(number_of_treatments,1);
if factor_level == 1
A = 1;
B = 1;
[M,V] = betastat(A,B);
for r = 1:1000
x = betarnd(A,B,number_of_treatments,1);
if var(100*x) >= V*100^2
di(:) = 100*x;
break
end
end
else
A = 6;
B = 6;
[M,V] = betastat(A,B);
for r = 1:1000
x = betarnd(A,B,number_of_treatments,1);
if var(100*x) <= V*100^2
di(:) = 100*x;
break
end
end
end
function eijk = generate_eijk(number_of_treatments, number_of_diseases,...
number_of_providers, factor_level)
eijk = zeros(number_of_treatments, number_of_diseases,...
number_of_providers);
for i = 1:number_of_treatments
for j = 1:number_of_diseases
if factor_level == 1
A = 1;
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B = 1;
[M,V] = betastat(A,B);
for r = 1:1000
x = betarnd(A,B,1,number_of_providers);
if var(x) >= V
eijk(i,j,:) = x;
break
end
end
else
A = 6;
B = 6;
[M,V] = betastat(A,B);
for r = 1:1000
x = betarnd(A,B,1,number_of_providers);
if var(x) <= V
eijk(i,j,:) = x;
break
end
end
end
end
end
function gj = generate_gj(number_of_diseases, factor_level)
gj = zeros(1,number_of_diseases);
if factor_level == 1
A = 1;
B = 1;
[M,V] = betastat(A,B);
for r = 1:1000
x = betarnd(A,B,1,number_of_diseases);
if var(10*x) >= V*10^2
gj(:) = 10*x;
break
end
end
else
A = 6;
B = 6;
[M,V] = betastat(A,B);
for r = 1:1000
x = betarnd(A,B,1,number_of_diseases);
if var(10*x) <= V*10^2
gj(:) = 10*x;
break
end
end
end
function si = generate_si(eij,number_of_treatments, factor_level)
si = zeros(number_of_treatments,1);
rgn = zeros(number_of_treatments,1);
ei = sum(eij,2);
if factor_level == 1
A = 1;
B = 1;
[M,V] = betastat(A,B);
for r = 1:1000
x = betarnd(A,B,number_of_treatments,1);
for i = 1:number_of_treatments
rgn(i) = 200*x(i)*ei(i)/sum(ei)...
+(-25+50.*rand())*x(i)*ei(i)/sum(ei);
end
if var(rgn) > V*(100)^2
si = rgn;
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break
end
end
else
A = 6;
B = 6;
[M,V] = betastat(A,B);
for r = 1:1000
x = betarnd(A,B,number_of_treatments,1);
for i = 1:number_of_treatments
rgn(i) = 200*x(i)*ei(i)/sum(ei)...
+(-10+20.*rand())*x(i)*ei(i)/sum(ei);
end
if var(rgn) <= V*(100)^2
si = rgn;
break
end
end
end
function ui = generate_ui(number_of_treatments, factor_level)
if factor_level == 2
ui = ones(number_of_treatments,1);
else
ui = 0.5*ones(number_of_treatments,1);
end
function vlk = generate_vlk(number_of_patient_types,...
number_of_providers, factor_level)
vlk = zeros(number_of_patient_types,number_of_providers);
for j = 1:number_of_patient_types
if factor_level == 1
A = 1;
B = 1;
[M,V] = betastat(A,B);
for r = 1:1000
x = betarnd(A,B,1,number_of_providers);
if var(100*x) >= V*100^2
vlk(j,:) = 100*x;
break
end
end
else
A = 6;
B = 6;
[M,V] = betastat(A,B);
for r = 1:1000
x = betarnd(A,B,1,number_of_providers);
if var(100*x) <= V*100^2
vlk(j,:) = 100*x;
break
end
end
end
end
function wil = generate_wil(number_of_treatments,...
number_of_patient_types, factor_level)
for l = 1:number_of_patient_types
if factor_level == 1
wil = 0.5*ones(number_of_treatments,number_of_patient_types);
elseif factor_level == 2
wil = ones(number_of_treatments,number_of_patient_types);
elseif factor_level == 3
wil = 2*ones(number_of_treatments,number_of_patient_types);
else
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wil = 2*rand(number_of_treatments,number_of_patient_types);
end
end

Procedures to generate A matrix for binary problems
function A = generateA(Number_of_treatments, Number_of_diseases)
A = zeros(Number_of_diseases, Number_of_diseases*Number_of_treatments);
r=0;
for j = 1:Number_of_diseases
for i = 1:Number_of_treatments
A(j,i+r)=1;
end
r=r+Number_of_treatments;
end

Procedures to generate Objective Function Value of Model 1
function z = ofv_Model1(xijk, eijk, ci)
%This function calculations the objective function value (ofv) for a given
%feasible solutions of Model 1 based on eijk and ci.
[Number_of_treatments,Number_of_diseases, Number_of_providers]=size(eijk);
% Initialize for two objectives
z = zeros(Number_of_providers,2);
for k = 1:Number_of_providers
for i = 1:Number_of_treatments
for j = 1:Number_of_diseases
z(k,1) = z(k,1) + ci(i)*xijk(i,j,k);
%total cost
z(k,2) = z(k,2) + eijk(i,j,k)*xijk(i,j,k); %total efficacy
end
end
end

Procedures to generate Objective Function Value of Model 2
function z = ofv_Model2(xij, eij, ci)
%This function calculations the objective function value (ofv) for a given
%feasible solutions of Model 2 based on eij and ci.
% Initialize for two objectives
z = zeros(1,2);
[Number_of_treatments,Number_of_diseases]=size(eij);
for i = 1:Number_of_treatments
for j = 1:Number_of_diseases
z(1) = z(1) + ci(i)*xij(i,j); %total cost
z(2) = z(2) + eij(i,j)*xij(i,j); %total efficacy
end
end

Procedures to generate Objective Function Value of Model 3
function z = ofv_Model3(xij, di, eij, si, ui, vj)
%This function calculates the objective function value of Model one as
%cost z(1) and efficacy z(2) for decision xij given coefficients ci and eij
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%Determing the number of treatments, diseases, and volume per treatment
Number_of_treatments = size(eij,1);
vi = xij*vj;
%Initialize objective function value as 1x2 vector
z=zeros(1,2);
%Sum total cost
for i = 1:Number_of_treatments
if vi(i) > 0
z(1) = z(1) + di(i) + si(i)*(vi(i))^ui(i);
end
end
%Sum total efficacy
z(2) = sum(dot(eij,xij));

Procedures to generate Objective Function Value of Model 4
function y = ofv_Model4(xij, eij, di, si, ui, Vl, Gl, wil, d, gj)
[number_of_treatments, number_of_diseases] = size(eij);
number_of_patient_types = size(Gl);
% Initialize for two objectives
y = zeros(2,1);
% Convert xij to xil
xil = zeros(number_of_treatments,number_of_patient_types);
for l=1:number_of_patient_types
for j=1:number_of_diseases
if find(d(l,:)==j)>0
for i=1:number_of_treatments
if xij(i,j) == 1
xil(i,l) = 1;
end
end
end
end
end
% Compute efficacy
trtinefficacy = ones(number_of_diseases,number_of_patient_types);
group_efficacy = zeros(1,number_of_patient_types);
Total_Efficacy = 0;
for l=1:number_of_patient_types
for j=1:number_of_diseases
if find(d(l,:)==j)>0
for i=1:number_of_treatments
trtinefficacy(j,l)=trtinefficacy(j,l)...
*(1-(eij(i,j)*xil(i,l))^wil(i,l));
end
group_efficacy(l)=group_efficacy(l)+gj(j)*(1-trtinefficacy(j,l))/sum(gj);
end
end
Total_Efficacy = Total_Efficacy +(Gl(l)/sum(Gl))*(Vl(l)/sum(Vl))*group_efficacy(l);
end
y(2) = Total_Efficacy;
% Compute cost objective to minimize
FC = 0;
VC = 0;
trtvolume = zeros(1,number_of_treatments);
for i=1:number_of_treatments
for l = 1:number_of_patient_types
trtvolume(i) = trtvolume(i) + Vl(l)*xil(i,l);
end
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if trtvolume(i) > 0
FC = FC + di(i);
end
VC = VC + si(i)*(trtvolume(i)^ui(i));
end
y(1) = FC + VC;

Procedures to generate Study 1
function [dx,dy,ndomStartx,ndomEndx,domStartx,domEndx,...
ndomStarty,ndomEndy,domStarty,domEndy,hits, misses, nglobalpts] = ...
dissertation_Study1v2(number_of_treatments, number_of_diseases,...
number_of_providers, number_of_replications)
%This program is designed to conduct a full factor experiment comparing the
%efficient frontier of model 1 to model 2 given the number of treatments,
%number of diseases, number of providers, and number of replications.
%Declare no. of levels for the four factors used in the experimental design
Factor1Levels = 2; %No. of levels for fixed cost variance
Factor2Levels = 2; %No. of levels for variance in percieved efficacy
Factor3Levels = 2; %No. of levels for variable cost variance
Factor4Levels = 2; %No. of levels for variance in provider patient volume
%Generate full factorial design matrix
dFF = fullfact([number_of_replications,Factor1Levels,Factor2Levels,...
Factor3Levels,Factor4Levels]);
%Count the number of experiments included in design for loop performance
%measurements
number_of_experiments = size(dFF,1);
%Initialize output variable eMargin to store the errors of each
%provider's perceived efficient frontier.
dx = zeros(number_of_experiments,number_of_providers);
dy = zeros(number_of_experiments,number_of_providers);
ndomStartx = zeros(number_of_experiments,number_of_providers,2);
ndomEndx = zeros(number_of_experiments,number_of_providers,2);
domStartx = zeros(number_of_experiments,number_of_providers,2);
domEndx = zeros(number_of_experiments,number_of_providers,2);
ndomStarty = zeros(number_of_experiments,number_of_providers,2);
ndomEndy = zeros(number_of_experiments,number_of_providers,2);
domStarty = zeros(number_of_experiments,number_of_providers,2);
domEndy = zeros(number_of_experiments,number_of_providers,2);
hits = zeros(number_of_experiments,number_of_providers);
misses = zeros(number_of_experiments,number_of_providers);
nglobalpts = zeros(number_of_experiments,1);
%Loop is used to determine providers' performance in each experiment
for experiment_number = 1:number_of_experiments
%Generate coefficients for model 1/2 based on parameters and designID
[eijk,eij,ci] = ...
study1_Coefficients(number_of_treatments, number_of_diseases,...
number_of_providers, dFF(experiment_number,:));
%Generate all feasible solutions for model 2
A = generateA(number_of_treatments, number_of_diseases);
b = ones(1,number_of_diseases);
model2BFSs = feassol(A,b);
%Initialize decision variable
xij = zeros(number_of_treatments, number_of_diseases);
%Loop to determine objective function values of all feasible solutions
number_of_BFSs = size(model2BFSs,2); %Number of basic feasible solns
objectiveValue_Model1 = zeros(number_of_BFSs,2,number_of_providers);
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objectiveValue_Model2 = zeros(number_of_BFSs,2);
for n = 1:number_of_BFSs
for j = 1:number_of_diseases
for i = 1:number_of_treatments
xij(i,j) = model2BFSs(number_of_diseases*(j-1)+i,n);
end
end
%Calculate the objective function value of an indexed solution for
%model 2
objectiveValue_Model2(n,:) = ofv_Model2(xij,eij,ci);

%Calculate the objective function value of an indexed solution
%using model 2 as if model 1 is a submodel for each provider.
for k = 1:number_of_providers
objectiveValue_Model1(n,:,k) = ofv_Model2(xij,eijk(:,:,k),ci);
end
end
%Use objective funtion values of all feasible solutions to determine
%efficient frontiers of providers in model 1 and model 2
efficient_frontier1 = concaveFront(objectiveValue_Model2);
for k = 1:number_of_providers
[sval,solutionID] = concaveFront(objectiveValue_Model1(:,:,k));
number_of_solutions = size(solutionID,1);
provider_frontier = zeros(number_of_solutions,2);
%determine provider k frontier in model 2
for r = 1:number_of_solutions
for j = 1:number_of_diseases
for i = 1:number_of_treatments
xij(i,j) = model2BFSs(number_of_diseases*(j-1)+i,solutionID(r));
end
end
provider_frontier(r,:) = ofv_Model2(xij,eij,ci);
end
%sort the provider frontier
[d1,d2] = sort(provider_frontier(:,1));
provider_frontier = provider_frontier(d2,:);
[dx(experiment_number,k),...
dy(experiment_number,k),...
ndomStartx(experiment_number,k,:),...
ndomEndx(experiment_number,k,:),...
domStartx(experiment_number,k,:),...
domEndx(experiment_number,k,:),...
ndomStarty(experiment_number,k,:),...
ndomEndy(experiment_number,k,:),...
domStarty(experiment_number,k,:),...
domEndy(experiment_number,k,:),...
hits(experiment_number,k),...
misses(experiment_number,k)]...
= measure3(provider_frontier,efficient_frontier1);
end
nglobalpts(experiment_number) = size(efficient_frontier1,1);
end

Procedures to generate Study 2
function [dx,dy,ndomStartx,ndomEndx,domStartx,domEndx,...
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ndomStarty,ndomEndy,domStarty,domEndy,hits, misses, nglobalpts,...
runtimes, enum_runtimes] = ...
dissertation_Study2a_v2(number_of_treatments, number_of_diseases,...
number_of_providers, number_of_replications)
% error = dissertation_Study2(number_of_treatments, number_of_diseases,...
% number_of_providers, number_of_replications)
%This program is designed to conduct a full factor experiment comparing the
%efficient frontier from the heuristic of model 3 to the actual
%efficient frontier of model 3 given the number of treatments,
%number of diseases, number of providers, and number of replications.
format long g
%Declare no. of levels for the five factors used in the experimental design
Factor1Levels = 2; %No. of levels for fixed cost variance
Factor2Levels = 2; %No. of levels for variance in percieved efficacy
Factor3Levels = 2; %No. of levels for variable cost variance
Factor4Levels = 2; %No. of levels for degree of volume discounts
Factor5Levels = 2; %No. of levels for variance in provider patient volume
%Generate full factorial design matrix
dFF = fullfact([number_of_replications,Factor1Levels,Factor2Levels,...
Factor3Levels,Factor4Levels,Factor5Levels]);
%Count the number of experiments included in design for loop performance
%measurements
number_of_experiments = size(dFF,1);
%Initialize output variable eMargin to store the error in the heuristic
%efficient frontier.
% error = zeros(number_of_experiments,2);
dx = zeros(number_of_experiments,1);
dy = zeros(number_of_experiments,1);
ndomStartx = zeros(number_of_experiments,2);
ndomEndx = zeros(number_of_experiments,2);
domStartx = zeros(number_of_experiments,2);
domEndx = zeros(number_of_experiments,2);
ndomStarty = zeros(number_of_experiments,2);
ndomEndy = zeros(number_of_experiments,2);
domStarty = zeros(number_of_experiments,2);
domEndy = zeros(number_of_experiments,2);
hits = zeros(number_of_experiments,1);
misses = zeros(number_of_experiments,1);
nglobalpts = zeros(number_of_experiments,1);
runtimes = zeros(number_of_experiments,1);
enum_runtimes = zeros(number_of_experiments,1);
% %Additional programming for scatterplot of Frontier
% figure('Name', 'HOLD ON approach');
% hold on
%Loop is used to determine heuristic performance in each experiment
for experiment_number = 1:number_of_experiments
efficient_frontier3 = [];
heuristic_frontier = [];
%Generate coefficients for model 3 based on parameters and designID
[ui,vj,eij,di,si] = ...
study2_Coefficients(number_of_treatments, number_of_diseases,...
number_of_providers, dFF(experiment_number,:));
tic
%Generate all feasible solutions for model 2
A=generateA(number_of_treatments, number_of_diseases);
b=ones(1,number_of_diseases);
model3BFSs=feassol(A,b);
%Initialize decision variable
xij = zeros(number_of_treatments, number_of_diseases);
%Loop to determine objective function values of all feasible solutions
objectiveValue_Model3 = zeros(size(model3BFSs,2),2);
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for n = 1:size(model3BFSs,2)
for j = 1:number_of_diseases
for i = 1:number_of_treatments
xij(i,j) = model3BFSs(number_of_diseases*(j-1)+i,n);
end
end
%Calculate the objective function value of an indexed solution for
%model 3
objectiveValue_Model3(n,:) = ofv_Model3(xij, di, eij, si, ui, vj);
end
%Use objective funtion values of all feasible solutions to determine
%efficient frontier of model 3
efficient_frontier3 = concaveFront(objectiveValue_Model3);
enum_runtimes(experiment_number) = toc;
%Use heuristic to estimate the efficient frontier of model 3
tic
[heuristic3_frontier,heuristic3_solution] = ...
model3_Hueristic(di, eij, si, ui, vj);
runtimes(experiment_number) = toc;
front1 = zeros(size(heuristic3_solution,1),2);
for n = 1:size(heuristic3_solution,1)
xij = xijStrtoMatrix(heuristic3_solution(n,:),number_of_treatments, number_of_diseases);
front1(n,:)=ofv_Model3(xij, di, eij, si, ui, vj);
end
[d1,d2] = sort(front1(:,1));
front1 = front1(d2,:);

%

%Compare model 1 to model 2 and store error per provider
error(experiment_number,:) = eMargin(front1,efficient_frontier3);
[dx(experiment_number),...
dy(experiment_number),...
ndomStartx(experiment_number,:),...
ndomEndx(experiment_number,:),...
domStartx(experiment_number,:),...
domEndx(experiment_number,:),...
ndomStarty(experiment_number,:),...
ndomEndy(experiment_number,:),...
domStarty(experiment_number,:),...
domEndy(experiment_number,:),...
hits(experiment_number),...
misses(experiment_number)]...
= measure3(front1,efficient_frontier3);
nglobalpts(experiment_number) = size(efficient_frontier3,1);

end

Procedures to generate Model 3 Heuristic
function [Front, Solution, Distance, iteration] = ...
model3_Hueristic(di, eij, si, ui, vj)
%STEP 0: Initialize heuristic parameters and solution
[number_of_treatments, number_of_diseases] = size(eij);
xijString0 = initializeXij(number_of_treatments, number_of_diseases);
Solution = xijString0;
%STEP 3: Repeat STEP 1-2 until the number of iterations is 100, previous
%solutions are the same a solutions of current iteration, or the distance
%between the previous front and the current front is less than epsilon.
iteration = 1;
Distance = 0;
N = number_of_treatments*number_of_diseases;
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nVars = N;
interval = 0;
while iteration < 100
%STEP 1: Find one-swap solutions with furthest distance from each
%point in the current set of solutions that fit in regions 1, 2, and 3.
swapFront = [];
swapSolution = [];
swapDistance = 0;
for r = 1:size(Solution,1)
[swapFront0, swapSolution0, swapDistance0] = ...
model3_findSwaps(Solution(r,:), di, eij, si, ui, vj);
swapFront = [swapFront; swapFront0];
swapSolution = [swapSolution; swapSolution0];
swapDistance = swapDistance + swapDistance0;
end
Front = swapFront;
Solution = swapSolution;
Distance = swapDistance;
%Condition for stopping based on solution or distance
if swapDistance > .5
iteration = iteration + 1;
else
iteration = 100;
end
%STEP 2: Ensure that front is concave after N solutions have been
%evaluated
interval = interval + r;
if interval >= nVars*5
[concaveFront, concaveSolns] = evalFrontSlope(Front, Solution);
interval = 0;
%
Front = [];
%
Solution = [];
Front = concaveFront;
Solution = concaveSolns;
end
end
%STEP 4: Ensure that the final front is concave then STOP
if isempty(Front)== 0
[concaveFront, concaveSolns] = evalFrontSlope(Front, Solution);
%
Front = [];
%
Solution = [];
Front = concaveFront;
Solution = concaveSolns;
end
function [swapFront, swapSolution, swapDistance] = ...
model3_findSwaps(xijString, di, eij, si, ui, vj)
%The program determines if more optimal points exists for the objective
%function value of xijString or P0 and returns these points in swapFront
%and their solutions in swapSolution. Scalar swapDistance totals distances
%from P0 to the most optimal points.
%STEP 0: Initialize the objective function value of xijString and other
%code variables
[Number_of_treatments, Number_of_diseases] = size(eij);
swapFront = []; %Front for more improving swap decisions
swapSolution = []; %Solutions for more improving swap decisions
N = size(xijString,2); %Number of solutions evaluated
xij0 = xijStrtoMatrix(xijString, Number_of_treatments, Number_of_diseases);
P0 = ofv_Model3(xij0, di, eij, si, ui, vj);
V0 = xij0*vj;
point = zeros(N,2); %Matrix to store ofv for the solutions being evaluated
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trialXij = zeros(N);
for r = 1:N
trialXij(r,:) = xijString ;%Matrix to store solutions being evaluated
end
%STEP1: Determine all possible swaps from P0
for i = 1:Number_of_treatments
for j = 1:Number_of_diseases
r = Number_of_diseases*(i-1)+j;
xij = xijStrtoMatrix(trialXij(r,:),...
Number_of_treatments, Number_of_diseases);
xij(:,j) = 0;
xij(i,j) = 1;
trialXij(r,:) = xijMatrixtoStr(xij);
Vi = xij*vj;
P1 = swapIncrement(xij0, xij, di, eij, ...
si, ui, V0, Vi);
point(r,:)= P0 + P1;
end
end
%STEP 2: Calculate the distances from P0 to all possible swaps from P0
alldistances = pdist([P0; point]); %Distances between all points
d = alldistances(1:N); %Distances from P0 to all possible swaps from P0
%STEP 3: Define points of furthest distance for swaps in regions one, two,
%and three
dtemp1 = 0; %Stores previous best distance evaluated in region 1, R1
dtemp2 = 0; %Stores previous best distance evaluated in region 2, R2
dtemp3 = 0; %Stores previous best distance evaluated in region 3, R3
mtemp1 = inf; %Stores previous best distance evaluated in region 1, R1
mtemp3 = 0; %Stores previous best distance evaluated in region 3, R3
region1Front = [];
region2Front = [];
region3Front = [];
for index = 1:N
if P0(1) > point(index,1) && P0(2) > point(index,2) %R1 criteria
m1 = (P0(2) - point(index,2))/(P0(1) - point(index,1));
if m1 < mtemp1
mtemp1 = m1;
dtemp1 = d(index);
region1Front = point(index,:);
region1Solution = trialXij(index,:);
end
elseif P0(1) >= point(index,1) && P0(2) <= point(index,2) %R2 criteria
if d(index)> dtemp2
dtemp2 = d(index);
region2Front = point(index,:);
region2Solution = trialXij(index,:);
end
elseif P0(1) < point(index,1) && P0(2) < point(index,2) %R3 criteria
m3 = (point(index,2) - P0(2))/(point(index,1) - P0(1));
if m3 > mtemp3
mtemp3 = m3;
dtemp3 = d(index);
region3Front = point(index,:);
region3Solution = trialXij(index,:);
end
end
end
% dtemp1 = 0; %Stores previous best distance evaluated in region 1, R1
% dtemp2 = 0; %Stores previous best distance evaluated in region 2, R2
% dtemp3 = 0; %Stores previous best distance evaluated in region 3, R3
% region1Front = [];
% region2Front = [];
% region3Front = [];
% for index = 1:N
% if P0(1) > point(index,1) && P0(2) > point(index,2) %R1 criteria
%
if d(index)> dtemp1
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%
dtemp1 = d(index);
%
region1Front = point(index,:);
%
region1Solution = trialXij(index,:);
%
end
% elseif P0(1) >= point(index,1) && P0(2) <= point(index,2) %R2 criteria
%
if d(index)> dtemp2
%
dtemp2 = d(index);
%
region2Front = point(index,:);
%
region2Solution = trialXij(index,:);
%
end
% elseif P0(1) < point(index,1) && P0(2) < point(index,2) %R3 criteria
%
if d(index)> dtemp3
%
dtemp3 = d(index);
%
region3Front = point(index,:);
%
region3Solution = trialXij(index,:);
%
end
% end
% end
%STEP 4: Define swapFront as best points that may exist in region one, two,
%and three which correspond to the points in swapSolution and sum their
%distances to P0.
if isempty(region1Front) == 0
swapFront = [swapFront; region1Front];
swapSolution = [swapSolution; region1Solution];
end
if isempty(region2Front) == 0
swapFront = [swapFront; region2Front];
swapSolution = [swapSolution; region2Solution];
end
if isempty(region3Front) == 0
swapFront = [swapFront; region3Front];
swapSolution = [swapSolution; region3Solution];
end
swapDistance = dtemp1 + dtemp2 + dtemp3; %Sums furthest distances

Procedures to generate Study 3
function [dx,dy,ndomStartx,ndomEndx,domStartx,domEndx,...
ndomStarty,ndomEndy,domStarty,domEndy,run_time,...
run_gens, run_exit, run_avgdist, run_spread, run_frontsize] =...
dissertation_Study3(number_of_treatments, number_of_diseases,...
number_of_providers, number_of_replications)
%This program is designed to conduct a full factor experiment comparing the
%efficient frontier of model 3 to model 4 given the number of
%treatments, number of diseases, number of providers, and number of
%replications. measure3 is used to assess performance. Initial population
%of the GA is solution set from Model 3.
number_of_patient_types = 0;
for j=1:number_of_diseases
number_of_patient_types = number_of_patient_types + ...
factorial(number_of_diseases)/(factorial(number_of_diseases-j)...
*factorial(j));
end
%Declare no. of levels for the five factors used in the experimental design
Factor1Levels = 2; %No. of levels for fixed cost variance
Factor2Levels = 2; %No. of levels for variance in percieved efficacy
Factor3Levels = 2; %No. of levels for variance disease severity
Factor4Levels = 2; %No. of levels for variable cost variance
Factor5Levels = 2; %No. of levels for degree of volume discounts
Factor6Levels = 2; %No. of levels for variance in provider patient volume
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Factor7Levels = 4; %No. of levels for efficacy curvature
dFF = fullfact([number_of_replications,Factor1Levels,Factor2Levels,...
Factor3Levels,Factor4Levels,Factor5Levels,Factor6Levels,...
Factor7Levels]);
number_of_experiments = size(dFF,1);
%Initialize output variables to store the model distance measures
dx = zeros(number_of_experiments,number_of_providers,3);
dy = zeros(number_of_experiments,number_of_providers,3);
ndomStartx = zeros(number_of_experiments,number_of_providers,2,3);
ndomEndx = zeros(number_of_experiments,number_of_providers,2,3);
domStartx = zeros(number_of_experiments,number_of_providers,2,3);
domEndx = zeros(number_of_experiments,number_of_providers,2,3);
ndomStarty = zeros(number_of_experiments,number_of_providers,2,3);
ndomEndy = zeros(number_of_experiments,number_of_providers,2,3);
domStarty = zeros(number_of_experiments,number_of_providers,2,3);
domEndy = zeros(number_of_experiments,number_of_providers,2,3);
%Initialize output variables to store GA performance measures
run_time = zeros(number_of_experiments,1);
run_gens = zeros(number_of_experiments,1);
run_exit = zeros(number_of_experiments,1);
run_avgdist = zeros(number_of_experiments,1);
run_spread = zeros(number_of_experiments,1);
run_frontsize = zeros(number_of_experiments,1);
run_frontPA = zeros(number_of_experiments,2);
run_frontPB = zeros(number_of_experiments,2);
for experiment_number = 1:number_of_experiments
efficient_frontier =[];
[eijk,gj,ui,vlk,wil,vjk,eij,ci,di,si,Gl,d] = ...
study4_Coefficients(number_of_treatments, number_of_diseases,...
number_of_providers, dFF(experiment_number,:));
Vl = sum(vlk,2);
Vj = sum(vjk,2);
%Generate all feasible solutions for model 2
A=generateA(number_of_treatments, number_of_diseases);
b=ones(1,number_of_diseases);
model2BFSs=feassol(A,b);
%Initialize decision variable
xij = zeros(number_of_treatments, number_of_diseases);
%Loop to determine objective function values of all feasible solutions
objectiveValue_Model1 = zeros(size(model2BFSs,2),2,number_of_providers);
objectiveValue_Model2 = zeros(size(model2BFSs,2),2);
objectiveValue_Model3 = zeros(size(model2BFSs,2),2);
for n = 1:size(model2BFSs,2)
for i = 1:number_of_diseases
for j = 1:number_of_treatments
xij(i,j) = model2BFSs(number_of_treatments*(j-1)+i,n);
end
end
%Calculate the objective function value of an indexed solution for
%model 2
objectiveValue_Model2(n,:) = ofv_Model2(xij,eij,ci);
%Calculate the objective function value of an indexed solution
%using model 2 as if model 1 is a submodel for each provider.
for k = 1:number_of_providers
objectiveValue_Model1(n,:,k) = ofv_Model2(xij,eijk(:,:,k),ci);
end
%Calculate the objective function value of an indexed solution for
%model 3

122
objectiveValue_Model3(n,:) = ofv_Model3(xij, di, eij, si, ui, sum(vjk,2));
end
%Use objective funtion values of all feasible solutions to determine
%efficient frontiers model 1 to 3
[~, solutionID2] = concaveFront(objectiveValue_Model2);
[~, solutionID3] = concaveFront(objectiveValue_Model3);
tic;
% Genetic Algorithm for model4 returns Fval4 as the efficient frontier
%Code to estimate percentiles of members in low cost and high efficacy
%regions
avgCi = zeros(number_of_treatments,1); %average cost of i
avgEi = ones(number_of_treatments,1); %average efficacy of i
for i = 1:number_of_treatments
avgCi(i)=(di(i)+si(i)*sum(Vl)^ui(i))/(sum(Vl));
for j = 1:number_of_diseases
avgEi(i) = avgEi(i)*(1-eij(i,j));
end
avgEi(i) = 1 - avgEi(i);
end
[minCRatio,minCIndex] = min(avgCi/sum(avgCi));
[maxCRatio,~] = max(avgCi/sum(avgCi));
[minERatio,minEIndex] = min(avgEi/sum(avgEi));
[maxERatio,maxEIndex] = max(avgEi/sum(avgEi));
% Genetic Algorithm for model4 returns Fval4 as the efficient frontier
NVARS4 = number_of_treatments*number_of_patient_types; %number of independent variables for the fitness function
popSize= 64*2;
popRand = randperm(popSize);
mypop = zeros(popSize,NVARS4);
M3frontSize = size(solutionID3,1);
for p = 1:popSize
if popRand(p) <= round(popSize*(minCRatio))
for l = 1:number_of_patient_types %original used mypop(p,...)..
mypop(popRand(p), number_of_treatments*(l-1)+minCIndex) = 1;
end
elseif popRand(p) >= min(round(popSize*minERatio),popSize-round(popSize*(minCRatio)))
for l = 1:number_of_patient_types
mypop(popRand(p), number_of_treatments*(l-1)+maxEIndex) = 1;
end
else
index = randi([1 M3frontSize]);
%index = popRand(p) - divisor*(floor((popRand(p) - 1)/divisor));
for j = 1:number_of_diseases
for i = 1:number_of_treatments
xij(i,j) = model2BFSs(number_of_diseases*(j-1)+i,...
solutionID3(index));
end
end
for l=1:number_of_patient_types
for j=1:number_of_diseases
if find(d(l,:)==j)>0
for i=1:number_of_treatments
if xij(i,j) == 1
mypop(popRand(p), number_of_treatments*(l-1)+i) = 1;
end
end
end
end
end
end
end
%
%

mypop = CreationFcn1(popSize, solutionID3, model2BFSs, d, ...
number_of_treatments, number_of_diseases, number_of_patient_types);
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LB4 = zeros(1, NVARS4);
UB4 = ones(1, NVARS4);
A4top = generateA(number_of_treatments, number_of_patient_types);
A4bottom = 0*A4top;
b4top = ones(number_of_patient_types,1);
b4bottom = zeros(number_of_patient_types,1);
Aeq4 = [];
beq4 = [];
options = gaoptimset(...
'InitialPopulation',mypop,...
'EliteCount', round(popSize*0.10), ...
'CrossoverFraction', .80,...
'CrossoverFcn',{@crossoverheuristic,1.2},...
'PopulationSize', popSize, ...
'StallGenLimit',100,...
'MutationFcn',{@mutationbyDerivatives,d, eij, ci, gj, si, ui, Vl, Gl, wil},...
'PlotFcns',@gaplotpareto);
%'PlotFcns',@gaplotpareto
A4 = [A4top;A4bottom];
b4 = [b4top;b4bottom];
% Genetic Algorithm for model4 returns Fval4 as the efficient frontier
FITNESSFCN4 = @(x)m4_multiobjective(x,eij, di, si, ui, Vl, Gl, wil, d, gj);
[x, Fval4, exitflag, output, population] = gamultiobj(FITNESSFCN4,NVARS4,A4,b4,...
Aeq4,beq4,LB4,UB4,options);
Fval4(:,2)=-1*Fval4(:,2);
concaveefficient_frontier = concaveFront(Fval4);
run_time(experiment_number) = toc;
run_gens(experiment_number) = output.generations;
run_exit(experiment_number) = exitflag;
run_avgdist(experiment_number) = output.averagedistance;
run_spread(experiment_number) = output.spread;
run_frontsize(experiment_number) = size(concaveefficient_frontier,1);
run_frontPA(experiment_number,:) = concaveefficient_frontier(1,:);
run_frontPB(experiment_number,:) = concaveefficient_frontier(size(concaveefficient_frontier,1),:);

%determine provider k frontier in model 4
for k = 1:number_of_providers
[~,solutionID1] = concaveFront(objectiveValue_Model1(:,:,k));
number_of_solutions = size(solutionID1,1);
provider_frontier = [];
provider_frontier = zeros(number_of_solutions,2);

for r = 1:number_of_solutions
for j = 1:number_of_diseases
for i = 1:number_of_treatments
xij(i,j) = model2BFSs(number_of_diseases*(j-1)+i,solutionID1(r));
end
end
provider_frontier(r,:) = ofv_Model4(xij, eij, di, si, ui, Vl, Gl, wil, d, gj);
end
%sort the provider frontier
[~,d2] = sort(provider_frontier(:,1));
provider_frontier = provider_frontier(d2,:);
[dx(experiment_number,k,1),...
dy(experiment_number,k,1),...
ndomStartx(experiment_number,k,:,1),...
ndomEndx(experiment_number,k,:,1),...
domStartx(experiment_number,k,:,1),...
domEndx(experiment_number,k,:,1),...
ndomStarty(experiment_number,k,:,1),...
ndomEndy(experiment_number,k,:,1),...
domStarty(experiment_number,k,:,1),...
domEndy(experiment_number,k,:,1)]...
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= measure3(provider_frontier,concaveefficient_frontier);
end
%determine model2 frontier in model 4
number_of_solutions = size(solutionID2,1);
model2_frontier = [];
model2_frontier = zeros(number_of_solutions,2);
for r = 1:number_of_solutions
for j = 1:number_of_diseases
for i = 1:number_of_treatments
xij(i,j) = model2BFSs(number_of_diseases*(j-1)+i,solutionID2(r));
end
end
model2_frontier(r,:) = ofv_Model4(xij, eij, di, si, ui, Vl, Gl, wil, d, gj);
end
%sort model2frontier
[~,d2] = sort(model2_frontier(:,1));
model2_frontier = model2_frontier(d2,:);
[dx(experiment_number,1,2),...
dy(experiment_number,1,2),...
ndomStartx(experiment_number,1,:,2),...
ndomEndx(experiment_number,1,:,2),...
domStartx(experiment_number,1,:,2),...
domEndx(experiment_number,1,:,2),...
ndomStarty(experiment_number,1,:,2),...
ndomEndy(experiment_number,1,:,2),...
domStarty(experiment_number,1,:,2),...
domEndy(experiment_number,1,:,2)]...
= measure3(model2_frontier,concaveefficient_frontier);
%determine model3 frontier in model 4
number_of_solutions = size(solutionID3,1);
model3_frontier = [];
model3_frontier = zeros(number_of_solutions,2);
for r = 1:number_of_solutions
for j = 1:number_of_diseases
for i = 1:number_of_treatments
xij(i,j) = model2BFSs(number_of_diseases*(j-1)+i,solutionID3(r));
end
end
model3_frontier(r,:) = ofv_Model4(xij, eij, di, si, ui, Vl, Gl, wil, d, gj);
end
%sort model3frontier
[~,d2] = sort(model3_frontier(:,1));
model3_frontier = model3_frontier(d2,:);
[dx(experiment_number,1,3),...
dy(experiment_number,1,3),...
ndomStartx(experiment_number,1,:,3),...
ndomEndx(experiment_number,1,:,3),...
domStartx(experiment_number,1,:,3),...
domEndx(experiment_number,1,:,3),...
ndomStarty(experiment_number,1,:,3),...
ndomEndy(experiment_number,1,:,3),...
domStarty(experiment_number,1,:,3),...
domEndy(experiment_number,1,:,3)]...
= measure3(model3_frontier,concaveefficient_frontier);
end
function [EfficientFront,FrontIndex] = concaveFront(f)
format long
[w,d2] = sort(f(:,1));
P = f(d2,:);
Q = d2;
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N = length(P);
mab = ones(1,N);
keep = ones(1,N);
for a = 1:(N - 1)
for b = (a + 1):N
if (P(a,1) == P(b,1))*(P(a,2) <= P(b,2))*keep(b) == 1
keep(a) = 0;
break
end
mab(b) = (P(b,2) - P(a,2)) / (P(b,1) - P(a,1));
end
if keep(a) == 1
for b = (a + 1):N
if b < N
if (mab(b) > max(mab((b + 1):N)))*(mab(b) > 0) == 0
keep(b) = 0;
end
else
if (mab(b) > 0) == 0
keep(b) = 0;
end
end
end
end
end
EfficientFront = zeros(sum(keep),2);
FrontIndex = zeros(sum(keep),1);
c = 1;
for i = 1:N
if keep(i) == 1
EfficientFront(c,:) = P(i,:);
FrontIndex(c,:) = Q(i);
c = c + 1;
end
end

